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Abstract 
The combination of cardiovascular and metabolic risk factors including obesity, 
dyslipidemia, hypertension, and insulin resistance, in combination with a prothrombotic 
and proinflammatory state, is a condition termed Metabolic Syndrome (METS). Twenty 
percent of the adult population is afflicted with METS which increases the risk of type-2 
diabetes mellitus and cardiovascular disease. Further, the presence of peripheral vascular 
disease (PVD) is tightly coupled with METS which is a perfusion-demand mismatch of 
blood supply to active skeletal muscle resulting in painful claudication and a late-stage 
potential for amputation. The underlying contributors of METS associated micro-
vasculopathies in the skeletal muscle, their impact on impaired perfusion, and the 
potential for reversibility remain unclear. Owing its hyperphagia to leptin signaling 
resistance, the obese Zucker rat (OZR) is a translationally relevant model for human 
METS and the associated micro-vasculopathies. The overall purpose of this thesis is to 
utilize a multi-scale approach, particularly intravital microscopy and isolate vessels, to 
garner a greater understanding of the observed OZR vasculopathies and to investigate the 
potential of therapeutic interventions for their reversibility. 
Project 1: The purpose was to identify any alterations in postcapillary and collecting 
venule function in the OZR compared to healthy controls. The OZR presented with 
impaired dilator reactivity and elevation in thromboxane A2 constrictor responses for 
both postcapillary and collecting venules. 
Project 2: The purpose was to identify the possible contributors of a disconnect for in-situ 
and ex-vivo vascular studies utilizing the OZR model. Using a multi-scale approach, 
Project 2 provides insight to this disconnect and reveals a heterogenous adrenergic 
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response in the OZR, giving rise to new potential avenues of study. 
Project 3: The purpose was to determine the potential for reversibility or restoration of 
established PVD using the chronic ingestion of an HMG-CoA inhibitor, atorvastatin, 
and/or the implementation of regular exercise. Following a seven-week intervention, the 
intervention groups revealed vascular improvements with the combination group having 
the greatest capacity for reversibility (in specific indices).  
Significance: Therefore, this thesis further advances the understanding of METS 
associated PVD as well as potential modes for improvement following its establishment. 
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Chapter 1  
1 Introduction and Review of the Literature 
 Metabolic Syndrome (METS) is a myriad of cardiovascular disease and metabolic 
disease risk factors including obesity, dyslipidemia, hypertension, and insulin 
resistance/impaired glycemic control tightly coupled with the presence of prothrombotic 
and proinflammatory physiological states (Frisbee & Delp, 2006). The Adult Treatment 
Panel III defines individuals with METS as having 3 of the following 5 criteria: 
abdominal obesity (waist circumference: men >102 cm and women >88 cm), elevated 
triglycerides (≥ 1.7 mmol/L), reduced HDL cholesterol (men<1.04 mmol/L and 
female<1.30 mmol/L), elevated blood pressure (≥130/≥85 mmHg), and elevated fasting 
glucose (≥6.1 mmol/L). 
1.1 Metabolic Syndrome 
 One in five adults between the ages of 18-79 are afflicted with METS (Riediger & 
Clara, 2011) which increases the risk of chronic diseases such as type II diabetes mellitus 
(T2DM) and cardiovascular disease (CVD) by approximately 5-fold and 2.6-fold, 
respectively (Grundy et al., 2002; Lakka, 2002).  CVD is defined by The American Heart 
Association as the presentation of poor heart function and/or inadequate blood supply to 
tissues/organ systems (AHA, 2017) and T2DM is a metabolic disease characterized by 
insulin resistance and impaired glycemic utilization for energy thereby starving working 
cells (ADA, 2015). Further, the resulting hyperglycemia may cause detrimental injuries 
to the eyes, heart, kidneys, and nerves (ADA, 2015). The World Health Organization 
reports CVD as the world’s leading cause of death and T2DM is ranked 7th (WHO, 
2018). More specifically, CVD and T2DM remain significant contributors to Canadian 
mortality rates, accounting for a combined 17% of all health care costs and 43% of all 
deaths in Canada (MetSC, 2018; Heron, 2007).  While METS may serve as a critical 
precursor for these chronic diseases, detrimental changes to peripheral vascular 
circulation, both structurally and functionally, are observed in parallel to the onset and 
progression of METS (Alberti et al., 2009; Chantler & Frisbee, 2015). 
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 A critical consequence of METS on the peripheral vasculature includes the 
reduction of blood supply and perfusion to working skeletal muscle (McClatchey et al., 
2017). Healthy, active muscles produce vasoactive, metabolic byproducts which promote 
increases in blood flow and perfusion to meet the increased metabolic demand of the 
working muscle. This physiological process is termed hyperemic response. Both human 
and animal models have revealed a decreased hyperemic response, despite similar muscle 
phenotypes, with METS compared to healthy controls (Jacqueline et al., 2016; Guarini et 
al., 2016). Further supported by both in-vivo and ex-vivo studies, the blunted hyperemic 
responses observed with METS and inflammation is a result of pathophysiological 
alterations in vessel dilation and constriction, vascular densities, and structural 
compositions (both atherogenic and non-atherogenic changes) all which will be covered 
with greater detail in subsequent sections (Butcher et al., 2013; Frisbee et al., 2009). 
Taken together, this supply/demand mismatching and its associated symptoms is known 
as peripheral vascular disease (PVD). 
 Pathophysiological alterations to the skeletal muscle may result in PVD which is 
independently associated with increases in CVD morbidity and mortality (Paraskevas et 
al. 2010) and that risk is further augmented when coupled with METS (Katsiki et al., 
2013; Wassink et al., 2018; Czel & Tefan, 2006). The National Health and Nutrition 
Examination Survey reported 38.4% of adults with METS, over the age of 40, were 
diagnosed with PVD (Sumner et al., 2012). Individuals afflicted with PVD may 
experience leg muscle fatigue, cramps, and pain during bouts of physical activity and, in 
the more extreme cases of vascular insufficiency when supply/demand mismatching 
occurs at rest, ulceration or gangrene of the feet may occur with a potential for limb 
amputation (Abdulhannan et al., 2012). Without revascularization, patients with vascular 
insufficiency will have a 19% risk of amputation within the first 6 months of initial 
treatment and 23% risk at one year (Marston et al., 2006).  
The Obese Zucker Rat as a Translational Model for Metabolic Syndrome 
 All of the material presented thus far has mainly been emphasized on 
epidemiological observations. While technology and public health records enable us to 
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non-invasively evaluate the broader outcomes of metabolic syndrome in humans, more 
invasive measures using animal models are essential to further investigate the 
vasculopathologies with greater control and detail. Most human studies introduce 
confounding variables such as genetic variations between patients. Albeit, these 
confounding variables may exist in animal models, but the ability to manipulate, 
measure, and control for their presence and/or severity is more feasible in utilizing this 
animal model.  
 The obese Zucker rat (OZR; fa/fa) is a translationally relevant model for 
examining metabolic syndrome. When co-expressed, the autosomal recessive mutation, 
fa, located on chromosome 5 causes a coding error for the leptin receptor gene, thereby 
producing an amino acid substitution on the leptin receptors and reducing leptin binding 
to the cerebral cell surface receptors in the choroid plexus and lateral ventricles of the 
brain (Yarnell et al., 1997; Kurtz, Morris, & Pershadsingh, 1989). Leptin is a key 
regulating hormone for energy consumption. Produced by the adipose tissue in proportion 
to fat storage, leptin is released into the circulatory system and interacts with the brain’s 
leptin receptors to signal for a decrease in consumption and an increase in energy 
expenditure (Halaas et al., 1995). As such, the OZR exhibits an impaired satiety reflex 
resulting in chronic hyperphagia which leads to the onset of excess body fat as early as 3-
4 weeks of life and, by week 14, approximately 40%-50% of the rat’s total body weight is 
adipose tissue while healthy controls from the same litter are measured at approximately 
20% (Artinano & Castro, 2009; Cleary et al., 1980). This rapid onset and progression of 
obesity is paralleled by increases in insulin resistance, dyslipidemia, hyperglycemia, and 
hypertension (Kurtz, Morris, & Pershadsingh, 1989).  
 Both humans with METS and the OZR experience similar systemic pathologies as 
well as prolonged periods of hypertriglyceridemia and insulin resistance prior to the overt 
development of type II diabetes mellitus (Frisbee & Delp, 2006). Further, the OZR 
demonstrates clinically relevant mild to moderate hypertension, which is comparable to 
the severity observed in humans with METS (Johnson et al., 2006) as well as a 
proinflammatory and prothrombotic state (Vaziri et al., 2005; Frisbee & Delp, 2006). 
Therefore, when considering the consistent parameters and the similar progression of 
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those parameters to that of the human conditions, the OZR represents an ideal 
translational model for garnering a greater understanding of METS. 
1.2 Biophysical Consequences 
 Although the cardiovascular system is essential for physiological functions such 
as oxygen and nutrient delivery to the body’s tissues, thermoregulation, combating 
diseases, and the clearance of metabolites and carbon dioxide from tissues, its most basic 
description includes that of a fluid (i.e. blood) transport system. As such, blood flow can 
be described using Ohm’s Law for fluids where flow (Q) is equal to the change in driving 
pressure (P) generated by the heart divided by the resistance (R).  
     Q=ΔP/R 
 Further, blood flow in a single vessel of the cardiovascular system can be 
determined via Poiseuille’s Law where the change in pressure across the vessel is 
multiplied by radius (r) then divided by the vessels length (l) and blood viscosity (η).  
   R=8ηl/ πr4                  Q=(ΔPπr4)/8ηl    
 Due to radius being heavily weighted in the context of fluid/blood resistance, a 
50% decrease in lumen diameter will yield a 16-fold increase in resistance. Therefore, 
radius is a key determinant for fluid resistance and flow in the vasculature. 
 In the dynamic cardiovascular system, vessel radii, mainly at the arteriolar level, 
is regulated via both intrinsic and extrinsic signals. Extrinsic systems such as metabolic 
signals, circulating hormones, and the sympathetic nervous innervation provide external 
regulatory signaling to the vasculature based on the needs of the supplied tissues. 
Intrinsic mechanisms such as myogenic control and shear stress further regulate vessel 
diameter based on intralumenal pressure and shear rate of blood against the lumen walls 
of the vessel, respectively. The range of vasodilator/constrictive responses may vary 
depending on the level of vasculature being interrogated such as the arteries, arterioles 
and their sub-units (Al-Khazraji et al. 2015; Chilian et al., 1989). However, the general 
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premise of these vascular controllers is to regulate vessel radii via vasoconstriction and 
vasodilation, dependent on the metabolic needs of perfused tissues. 
 In the presence of obesity, dyslipidemia, and impaired glycemic control, the 
vascular dilator and constrictor responses in the skeletal muscle are altered to favor that 
of a decrease in vessel radius at rest and in response to both extrinsic and intrinsic 
controllers compared to healthy controls. In accordance with Ohm’s Law for Fluids and 
Poiseuille’s Law, a system which favors a vasoconstrictive state, thereby decreasing radii 
and increasing resistance, will result in a proportional increase in blood pressure and/or a 
decrease in flow. This insufficiency in blood supply to tissues during higher metabolic 
demand can contribute to myocardial infarctions, stroke, and intermittent claudication 
with a potential to result in limb amputation. Biological contributors to these biophysical 
consequences involved in decreased vessel radii compared to healthy controls will be 
further defined in subsequent sections. Additionally, insulin resistance and the resulting 
hyperinsulinemia (Wu et al., 2000) can exert hypertrophic effects on vascular smooth 
muscle cells (i.e. vessel proliferation) and promote atherogenic monocyte adhesion and 
infiltration (Yeh, 2004).  These pathologies can decrease vessel radii (Hutcheson et al., 
2014; Cersosimo et al., 2014) as well as cause decreases in vessel wall deformation 
(Chantler & Frisbee, 2015) thereby further limiting skeletal muscle perfusion (Fossum et 
al., 1998). 
 While temporal regulatory dysfunction of the arterioles is a key contributor 
toward increases in blood flow resistance in the skeletal muscle vasculature of those with 
METS, there are detrimental spatial alterations as well. The Frisbee lab reported 
significant reductions in microvessel densities (i.e. vascular rarefaction) within the 
gastrocnemius muscle of OZR compared to healthy controls (Frisbee, 2003) and 
reductions in vessel density have been shown to exert the largest effect on tissue oxygen 
levels (Greene et al., 1992). As such, tissues of high metabolic demand, but reduced 
densities may result in reduced oxygen levels which could limit the metabolic activity 
and performance of that tissue (Greene et al., 1992). Optimal capillary-to-tissue 
(cylinder) density ratio for sufficient oxygen diffusion across tissues can be described 
using the Krogh Cylinder Model (Krogh, 1919) with respect to the partial pressure 
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gradient of O2 (Fig. 1-A). In this model, decreases in capillary density, in the absence of 
compensatory alterations in tissue density, can shift this optimal ratio and create areas of 
hypoxia as the cylinder becomes too large for the diffusion of O2 across tissue (Fig. 1-B). 
Figure 1-A: Krogh Cylinder Model describing optimal capillary/tissue ratio and O2 
diffusion to surrounding tissue 
  
(Graphic retrieved from PerfusionTheory.com; link in 1.7)  
 
 
 
 
 
 
 
 
 7 
 
Figure 1-B: Krogh Cylinder Model describing suboptimal capillary/tissue ratios and 
resulting areas of hypoxia 
 
 
 
(Graphic retrieved from PerfusionTheory.com; link in 1.7) 
 In addition to implications on gas and nutrient delivery/clearance to the perfused 
tissue, rarefaction can promote increases in overall network resistance (Greene et al., 
1989). Figure 2 describes the decrease in the overall resistance (arbitrary numbers) for 
vessels oriented in parallel to an overall value lower than that of any single vessel within 
the network and how that overall resistance will increase if one of the parallel vessels is 
removed, if other variables remain constant. Therefore, vessels in parallel decrease the 
overall network resistance and reducing the number of vessels in parallel will increase the 
overall resistance of a network. In the context of METS, fifteen-week-old OZRs have a 
20-25% reduction in microvessel density (Frisbee, 2003) which can promote both 
increases in network resistance and decreases in oxygen delivery thereby contributing to 
reduced blood flow and oxygenation of working skeletal muscles. 
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Figure 2: Example of increases in network resistance with decreases in parallel vessels 
(arbitrary units).  
  
     
 Metabolic syndrome is associated with various biophysical consequences such as 
shifted lumen diameters in response to pharmacological and/or muscle stimulation which 
favors a more vasoconstrictive state compared to healthy controls. Coupled with 
structural changes and rarefaction, there is a multitude of factors that increase vascular 
resistance and decrease muscle perfusion thereby contributing to the high prevalence of 
PVD with METS. Although most of microcirculatory research interrogates the arterial 
side, previous studies show the earliest changes in vascular dysfunction can be observed 
on the venular side of skeletal muscle networks with an emphasis on retrograde 
rarefaction from the venules to the arterioles (Frisbee et al., 2014).  Some of the 
contributing pathologies of these biophysical consequences are covered in the following 
sections, with respect to the context of this dissertation. 
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1.3 Biological Contributors to Biophysical Detriments 
 While biophysical detriments associated with METS contribute to the obstruction 
and reduction of blood flow to perfused skeletal muscles, the cause of these detriments 
are rooted in the biological pathologies linked with obesity, impaired glycemic control, 
and dyslipidemia.  This dissertation will explore some of those pathologies and their 
contributions to increases in vascular resistance on both the arteriole side and the venular 
side of the microcirculation in the OZR. Further, we will explore interventional and 
treatment strategies for reversing these pathological contributors with the primary goals 
of decreasing vascular resistance, increasing tissue perfusion, and increasing 
microvascular density.  
Endothelial nitric oxide 
 Endothelial dysfunction is a key vascular consequence of METS and chronic 
inflammation, by which there is a decrease in nitric oxide (NO) bioavailability compared 
to healthy controls under both resting and stimulated conditions. In short, NO is an 
essential molecule which signals for vascular smooth muscle relaxation/dilation which is 
produced in the endothelium and can be stimulated via acetylcholine, bradykinin, and/or 
the shear stress created by blood flow against the endothelial wall which up regulates 
intracellular calcium release to activate the NO synthesizing enzyme, endothelial nitric 
oxide synthase (eNOS; Fig. 3). Following this, eNOS converts L-arginine to L-citrulline 
and synthesizes NO which diffuses out of the endothelial cell to the neighboring vascular 
smooth muscle to dephosphorylate guanine triphosphate to elicit vasodilation and prevent 
smooth muscle proliferation/remodeling thereby promoting decreases in vascular 
resistance and vessel stiffening, respectively. However, the reduced NO bioavailability 
associated with METS can shift the vasculature to a more vasoconstrictive state, thus 
increasing vascular resistance which is a key contributor to elevated blood pressure and 
hypertension. Furthermore, clot formation and leukocyte recruitment are both inhibited 
by NO (Hossain et al., 2012), therefore the decrease in NO bioavailability with METS 
can contribute to the observed prothrombotic and proinflammatory state.  
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Figure 3: Endothelial nitric oxide production 
 
 
Proinflammation and oxidative stress 
 While the presence of a proinflammatory state are reliably associated with METS 
(Ford, 2003), they are not typically considered inclusion criteria for the clinical diagnosis 
of METS. However, both human and animal models with metabolic syndrome risk 
factors consistently report evidence of elevated markers including, but not limited to 
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and c-reactive protein (CRP), all of 
which can be attributed to excess fat stores (Goodwill, 2008; Ford, 2003; Erdembileg et 
al., 2015; Bickel et al., 2002). TNF-α cytokines can impact endothelial function (Singer 
and Granger, 2007), increase reactive oxygen species (ROS) production (Agharazii et al., 
2015), alter glucose metabolism of the skeletal muscle via the inhibition of insulin 
receptor tyrosine kinase (Hotamisligil et al., 1996), promote smooth muscle cell 
proliferation, and increase monocyte cell adhesion and infiltration (Yeh, 2004). IL-6 is a 
key regulator for CRP production which is a clinical marker of inflammation that serves 
as an early predictor for cardiovascular disease, including asymptomatic patients (Ridker 
et al., 2002). Elevated CRP mediated activity can directly inhibit nitric oxide (NO) 
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production via inhibition of eNOS and endothelial dysfunction (Jialal, 2009) and 
contribute to the elevated levels of ROS production associated with a pro-inflammatory 
state (Prasad, 2004; Singer and Granger, 2007).  
 ROS is a chemically reactive byproduct of oxidative metabolism which is 
essential for cell signaling, immune response, as well as non-pathological apoptosis and 
contain one or more oxygen atoms and unpaired electrons. The highly reactive 
superoxide anion (O2-·) is the initial ROS produced by mitochondrial metabolism which 
is normally and rapidly transformed into H2O2 and then to water via the antioxidant 
enzymes superoxide dismutase (SOD) and catalase/glutathione peroxidase, respectively. 
However, oxidative stress, or elevations in ROS production beyond that of endogenous 
antioxidant systems, can result in the alteration of essential cellular proteins and increases 
in proteolytic susceptibly (Davies et al., 1986).  There are a multitude of studies 
connecting oxidative stress with observed vasculopathies associated with impaired 
glycemic control and insulin resistance, cardiovascular diseases, and a multitude of other 
diseases (Agharazii et al., 2015; Frisbee & Delp, 2006; Davies et al., 1986). A key 
consequence of excess ROS in the context of vascular function is its reactivity with 
endothelial derived NO to form elevated levels of peroxynitrate, which can uncouple 
eNOS, thus decreasing both the production and the bioavailability of NO (Fig 4; 
Goodwill and Frisbee, 2012).  
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Figure 4: Superoxide pathways  
 
 
 Additionally, vascular necrosis/rarefaction can be linked to increased oxidative 
stress as NO is essential for the structural maintenance of the vasculature and 
angiogenesis (Cooke and Losordo, 2002). Decreases in vascular density may lead to 
increases in hypoxia which can further exacerbate ROS production and contribute to a 
self-perpetuating pathology (Chandel et al., 1998). Taken together, ROS production is a 
self-propagating phenomenon which is detrimental to normal cellular function.  In the 
context of this dissertation, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL), a 
free radical scavenger and superoxide mimetic, is used to measure the contribution of 
ROS on the blunted dilatory response of the OZR vasculature compared to healthy 
controls.  
 An additional consequence includes a ratio shift in prostacyclin (PGI2) and 
thromboxane (TxA2) production attributed mainly to oxidative stress (Goodwill et al, 
2008), dyslipidemia, and the oxidization of low density lipoproteins (Palinski et al. 1989; 
Pfister & Campbell, 1996). PGI2 and TxA2 are two well known, vasoactive end products 
of arachidonic acid (AA) metabolism by cyclooxygenase to prostaglandin endoperoxide 
H2 (Figure 5: AA metabolism).  PGI2 and TxA2 are known to elicit opposite actions on 
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coagulation and vasodilatory/vasoconstrictive response. PGI2 is recognized more so as 
the homeostatic product of AA metabolism as it promotes vasodilation and has anti-
coagulant properties, whereas TxA2 is a potent vasoconstrictor which promotes red blood 
cell and platelet aggregation and is more so observed at the sight of acute injuries or in 
pathophysiological conditions.  
Figure 5: Arachidonic acid metabolism cascade 
  
 In the presence of insulin resistance there is a shift in arachidonic acid metabolism 
which favors TxA2 production (Hishinuma, 2001) which has been attributed to the 
inactivation of prostacyclin synthase via interaction with the elevated levels of 
peroxynitrite (Davis & Zou, 2005). Further, it has been suggested impaired glycemic 
control may promote protein kinase C activity with ensuing increases in the inducible 
isoform, cyclooxygenase-2, activity to produce elevated TXA2 production in circulating 
leukocytes (Nusing et al., 1993). This shift promotes a more vasoconstrictive state of the 
vessels at rest and in response to the TXA2 mimetic U46619 (Goodwill, 2008) thereby 
decreasing the lumen size and contributing to increases in vascular resistance. 
Additionally, the coagulative actions of TXA2 promotes the prothrombic state observed 
with METS risk factors which increases the risk of clot/thrombotic formations and 
associated diseases and detrimental cardiovascular events such as stroke and heart attack. 
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Adrenergic Control 
 The altered vasodilatory signaling and reactivity observed with METS and models 
of METS is well established. Previous studies have also demonstrated the decrease in 
skeletal muscle lumen diameter in the OZR can be further credited to an elevated 
constrictor response to sympathetic nervous system (SNS) innervation compared to 
healthy controls (Stepp & Frisbee, 2002). The SNS elicits vasoconstriction via the release 
neuronal signals and the interaction with their respective receptors (R) which includes the 
following: nor-adrenaline (α1-R & α2-R; adrenergic), adenosine triphosphate (P2X1-R; 
purinergic), and neuropeptide Y (Y1-R; peptidergic). Vascular responses to these signals 
within the arteriole microcirculation experience heterogeneous distribution where 
proximal arterioles are largely under adrenergic control and the distal arterioles are more 
so under purinergic and/or peptidergic control (Anderson & Faber, 1991; Al-Khazraji et 
al. 2015).  
 It has been suggested the decreases in hyperemic response to occlusion and the 
more vasoconstricted state observed in OZR may be attributed to the augmentation of α1-
adrenergic response, validated by the rescuing effects of adrenergic blockers such as 
prazosin and phentolamine (Frisbee, 2006). This dissertation will examine the α-
adrenergic response observed using a mutli-scale (in-situ, in-vivo, and ex-vivo) approach 
at various levels of microcirculation (feed arteries, arterioles, terminal/precapillary 
arteries) to garner a greater understanding of the variability observed when using single 
point interrogations at a single level of the vasculature.  While the majority of previous 
research in the context of microcirculation and blood flow resistance has focused on the 
interrogation of arteries and resistance arterioles, we also examine the effects of α-
adrenergic mediation of venule diameters to identify potential contributors to the overall 
increase in vascular resistance observed in METS and METS models. 
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1.4 Translational Interventions for PVD: Chronic Exercise 
and/or HMG-CoA Reductase Inhibitor 
 An existing clinical and translational disparity in animal models with METS 
associated PVD is that many of the employed interventions are relevant for blunting the 
severity of vasculopathies of the developing PVD. However, from a clinical stance, this 
may not serve as the most relevant model as many patients seek medical assistance due to 
claudication or pain in their extremities when performing physical activity, meaning PVD 
is already well established. Therefore, animal studies which employ early interventions, 
prior to the establishment of PVD, are not translationally relevant for humans presenting 
with established PVD. In the context of this dissertation, we employ interventions 
following the establishment of PVD which includes regular, physical activity/exercise 
and/or the chronic ingestion of the HMG-CoA inhibitor, atorvastatin. 
Chronic Exercise 
 It is well established that regular exercise can improve obesity, insulin resistance, 
and dyslipidemia in both humans and animals (Moller & Kaufman, 2005; Becker-
Zimmermann et al., 1982). Additionally, exercise has been shown to improve vascular 
densities in skeletal muscle, both trained/locomotive muscles (Frisbee, 2006) and non-
trained/systemic muscles (Qui et al., 2018), and improves NO bioavailability (Machado 
et al., 2016). NO bioavailability plays a critical role in angiogenic incompetence and 
rarefaction (Machado et al., 2016; Ungvari et al., 2018) and this dependency has been 
suggested to be the major underlying mechanism of microvascular rarefaction in METS 
(Frisbee, 2005). 
 A multitude of previous studies indicate improvements in NO bioavailability via 
increases in eNOS expression and activity for both healthy controls (Parker et al., 2011) 
and disease states (Orr et al., 2009; Fiuza-Luces et al., 2018). A potential contributor to 
this upregulation may be in adaptation to the regular increases of exercise induced shear 
stress from blood flow, a potent stimulus for NO production and vasodilation (Fleming 
and Busse, 2003). Improvements in NO bioavailability are paralleled by decreases in 
ROS generation and improvements in antioxidant systems (Kojda & Hambrecht, 2005). 
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Potential mechanisms include increases in superoxide dismutase, catalase, and peroxidase 
(Berzosa et al., 2011) as well as decreases in the NADPH oxidase production of ROS 
(Rush et al., 2003). Taken together, these exercise-induced improvements can result in 
increases of NO bioavailability in METS models thereby promoting angiogenesis to 
combat rarefaction and improve many of the other previously listed pathologies 
associated with impaired NO bioavailability.  
HMG-CoA Inhibition  
 Clinically, the inhibition of liver enzyme 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMG-CoA) is commonly used in an effort to reduce circulating cholesterol 
levels, thus the target for cholesterol lowering drugs such as the HMG-CoA reductase 
inhibitor, atorvastatin (ATOR). However, statins also have pleiotropic effects and are 
therefore increasingly used for reasons beyond lowering cholesterol levels, including 
anti-inflammation (Fujita et al., 2007). Although the mechanisms are unclear, statins are 
associated with improvements in inflammatory markers and endothelial cell function 
which result in better outcomes of inflammation-linked vascular diseases (Haslinger-
Löffler, 2008). More specifically, ATOR has been reported to decrease the expression of 
the previously mentioned inflammatory cytokines (IL-6 and TNF-α), decrease CRP, and 
improve defense systems against reactive oxygen species (Rabkin et al., 2013; Sodha et 
al., 2015) thus improving the previously mentioned, associated detriments observed with 
established PVD. 
1.5 Specific Aims 
1. To determine alterations for post-capillary venular structure/function in OZR and the 
extent this contributes to elevated network resistance and impaired mass 
transport/exchange. These experiments employ intravital imaging of in situ skeletal 
muscle with specific physiological and pharmacological challenges to determine venular 
hemodynamic and vasomotor diameter responses in METS. 
 
2. To determine the role of adrenergic signaling and its interaction with altered 
endothelial function on resistance in pre-capillary, arteriolar networks of OZR and how it 
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may contribute to skeletal muscle perfusion. These experiments employ in vivo, in situ, 
and ex vivo conditions to interrogate interactions between adrenergic responses and their 
influence on vessel diameters. 
 
3. To determine the potential for reversibility of OZR microvasculopathies using exercise 
and atorvastatin. These experiments employ intravital microscopy of in situ skeletal 
muscle and the study of ex vivo arterioles to determine alterations in vessel diameter 
control, blood flow distribution, and bulk perfusion within arteriolar networks.   
1.6 Significance 
 METS and PVD continue to burden the health of afflicted individuals via 
decreases in quality of life and increases in both morbidity and mortality. Further, these 
burdens extend to higher healthcare spending. Although strides have been made to 
understand these diseases, many of the underlying mechanisms remain unclear. 
Therefore, this dissertation seeks to further advance the understanding of METS 
associated PVD and explore potential modes for improvement following its 
establishment.   
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KEY POINTS: 
• With the development of the metabolic syndrome, both post-capillary and collecting 
venular dilator reactivity within the skeletal muscle of obese Zucker rats (OZR) is 
impaired.   
• The impaired dilator reactivity in OZR reflects a loss in venular nitric oxide and PGI2 
bioavailability, associated with the chronic elevation in oxidant stress.  
• Additionally, with the impaired dilator responses, a modest increase in adrenergic 
constriction, combined with an elevated thromboxane A2 production may contribute 
to impaired functional dilator and hyperemic responses at the venular level.   
• The shift in skeletal muscle venular function with development of the metabolic 
syndrome on issues such as aggregate microvascular perfusion resistance, mass 
transport and exchange within with capillary networks, and fluid handling across the 
microcirculation are compelling avenues for future investigation. 
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2.1 Abstract 
While research into vascular outcomes of the metabolic syndrome has focused on 
arterial/arteriolar and capillary levels, investigation into venular function and how this 
impacts responses has received little attention.  Using the in situ cremaster muscle of 
obese Zucker rats (OZR; with leans (LZR) as controls), we determined indices of venular 
function.  At ~17 weeks of age, skeletal muscle post-capillary venular density was 
reduced by ~20% in LZR vs. OZR, although there was no evidence of remodeling of the 
venular wall.  Venular tone at ~25 µm (post-capillary) and ~75 µm (collecting) diameter 
was elevated in OZR vs. LZR.  Venular dilation to acetylcholine was blunted in OZR vs. 
LZR due to increased oxidant stress-based loss of nitric oxide bioavailability (post-
capillary) and increased α1- (and α2-) mediated constrictor tone (collecting).  Venular 
constrictor responses in OZR were comparable to LZR for most stimuli, although 
constriction to α1 adrenoreceptor stimulation was elevated.  In response to field 
stimulation of the cremaster muscle (0.5, 1, 3 Hz), venular dilator and hyperemic 
responses to lower frequencies were blunted in OZR, but responses at 3 Hz were similar 
between strains.  Venous production of TxA2 was higher in OZR than LZR and 
significantly higher than PGI2 production in either following arachidonic acid challenge.  
These results suggest that multi-faceted alterations to skeletal muscle venular function in 
OZR may contribute to alterations in upstream capillary pressure profiles and the trans-
capillary exchange of solutes and water under conditions of metabolic syndrome. 
Key words:  venous function, microcirculation, metabolic syndrome, skeletal muscle 
blood flow 
Abbreviations: DPEP IV, dipeptidyl peptidase-4; GS-1, griffonia simplicifolia 1; L-
NAME, Nω-Nitro-L-arginine methyl ester hydrochloride; LZR, lean Zucker rat; OZR, 
obese Zucker rat; PGI2, prostacyclin; TEMPOL, 4-hydroxy-2,2,6,6-tetramethylpiperidin-
1-oxyl; TxA2, thromboxane A2 
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2.2 Introduction 
 It is well established that the growing incidence and prevalence of the metabolic 
syndrome presents a consistent threat to aggregate public health cardiovascular outcomes 
across many societies and developed economies (Mameli et al., 2017; Tune et al., 2017; 
Vassalo et al., 2016).  This syndrome is broadly defined as the combined presentation of 
obesity, impaired glycemic control, atherogenic dyslipidemia and hypertension, with the 
additional contributing conditions of pro-oxidant, pro-thrombotic and pro-inflammatory 
phenotypes (American Heart Association, 2017; Vassalo et al., 2016).  While this 
condition is present in a growing number of afflicted persons worldwide, its influence on 
morbidity and mortality (Global Burden of Metabolic Risk Factors for Chronic Diseases 
Collaboration, 2014), as well as the economic costs that must be borne by society 
(Shamsedden et al., 2011; Trasande and Elbel, 2012), mandate the detailed investigation 
into this multi-pathology state. 
 While enormous investment has been made in understanding the impact of the 
metabolic syndrome on arterial/arteriolar and capillary function (Goodwill et al., 2012, 
Lemaster et al., 2017, Tune et al. 2017), dedicated study of venular function has been 
limited and has largely focused on leukocyte-endothelial cell interactions as well as 
inflammatory and pro-thrombotic processes (Estato et al., 2017; Iba et al., 2012; Scallan 
et al., 2015).  Although these are important aspects of altered venular function, our 
understanding of venous tone regulation and its potential contribution to integrated 
microvascular function through the transition from health to disease is far from complete.  
Population health studies, using the retinal microcirculation as a “window” into altered 
venular function, suggest that the control of venular diameter and venular network 
structure can be significantly altered with metabolic disease (Lammert et al., 2012; Wong 
et al., 2004; Zhao et al., 2012).  However, there has been a limited attempt at 
investigating these relationships in relevant animal models. 
 The obese Zucker rat (OZR; fa/fa) represents a translationally-relevant model to 
study the metabolic syndrome, as cardiovascular disease in this model tracks well with 
cardiovascular (dys)function in afflicted humans.  OZR develop the metabolic syndrome 
due to chronic hyperphagia based in leptin resistance, and rapidly develop all of the 
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systemic phenotypes listed above to comparable levels of severity to that commonly 
identified in human subjects.  Also similar to the health outcomes in humans, OZR 
exhibiting the metabolic syndrome suffer from a progressive vasculopathy that ultimately 
develops into overt peripheral vascular disease (Frisbee and Delp, 2006), albeit one 
without the development of significant atherosclerotic lesions.  While there has been 
extensive interrogation of the impact of metabolic syndrome on the arterial side of the 
microcirculation in OZR and in comparable models (Tune et al., 2017), there has been 
less effort devoted to understanding the potential for altered venular function under these 
conditions and the potential impact on integrated microvascular function.   
The purpose of the present study was to begin to understand how the function of in situ 
post-capillary and collecting venules from obese Zucker rats manifesting the full 
metabolic syndrome can be impacted as a result of the multi-pathology state.  To assess 
this, we used an array of physiological and pharmacological challenges to understand 
how function is altered at these two levels within the venular networks.  The present 
study tested the hypothesis that post-capillary and collecting venular function in the in 
situ skeletal muscle of OZR is altered in a manner that can increase venular blood flow 
resistance and negatively impact function within the capillary networks. 
2.3 Materials and Methods 
 Ethical Approval: All procedures in the present study had received prior review and 
approval by the Institutional Animal Care and Use Committee.  All animal use procedures, 
including anesthesia and euthanasia, conform to standards established by the UK/European 
Union legislation (set out in in ASPA Schedule 1 in the UK and in Annex IV in the 
European Directive 2010/63/EU), the Canadian Council for Animal Care and the United 
States Department of Agriculture.  All details of animal use are provided in the subsequent 
paragraphs. 
Animals: Male lean (LZR, Harlan/Envigo) and obese Zucker rats (OZR, Harlan/Envigo) 
were acquired at 6-7 weeks of age, and after one week of acclimation, were aged to ~17 
weeks of age.  All animals were fed standard chow and tap water ad libitum for all 
experiments.  On the experiment day, after an 8 hour fast, rats were anesthetized with 
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injections of sodium pentobarbital (50 mg•kg-1 i.p.), and all rats received tracheal intubation 
to facilitate maintenance of a patent airway.  In all rats a carotid artery and an external 
jugular vein were cannulated for determination of arterial pressure and for intravenous 
infusion of additional substances as necessary (e.g., anesthesia, heparin, etc.).  Any animal 
in which mean arterial pressure was found to be below 85 mmHg (<5% in both LZR and 
OZR), or where it had decreased by more than 15% from that following equilibration 
(without any pharmacological intervention; ~5% in LZR, ~10% in OZR) was not used in the 
present study.  Blood samples were drawn from the venous cannula for determination of 
glucose and insulin concentrations (Millipore, Billerica, MA) as well as 
cholesterol/triglyceride levels (Wako Diagnostics, Richmond, VA), and nitrotyrosine (Oxis 
International. Foster City, CA).  Blood gases were determined using a Corning RapidLab 
248 Blood Gas Analyzer (Siemens Medical Solutions, Malvern, PA). Unless otherwise 
noted, all drugs and chemicals were purchased from Sigma-Aldrich (St. Louis, MO).  
Adequate depth of anesthesia was confirmed at ~15 minute intervals by monitoring 
ventilation patterns and noting an absence of whisker movement, startle and toe-pinch 
withdrawal reflexes.  Additional anesthetic was introduced in 10 mg•kg-1 increments, as 
needed, through the jugular vein cannula.  After all experiments, the anesthetized rat was 
euthanized with an intravenous overdose of sodium pentobarbital (>200 mg•kg-1) followed 
by a bilateral pneumothoracotomy and physical removal of the heart. Due to the lasting 
effects of some of the pharmacological interventions and the inherent difficulties in 
reversing them, not all observations could be gathered from every animal.  As a result, in 
specific experiment groups, the actual number of animals used can exceed the number of 
specific observations.  This was done in order to preserve quality and experiment rigor.  For 
clarity, total animal numbers used for the present study, and their distribution across the 
experimental groups, are summarized in Table 1.   
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Table 1.  Animal numbers, experimental group distributions and condition observation 
numbers within groups for the present study.  All other experiment data came from ex 
vivo tissue analyses recovered from within these animal groups.  Please see text for 
details. 
 
 
Preparation of In Situ Cremaster Muscle:  In each rat, the left cremaster muscle was 
prepared for television microscopy (Butcher et al., 2013).  After completion of the 
preparation, the cremaster muscle was superfused with PSS, equilibrated with a gas mixture 
containing 5% CO2 and 95% N2, and maintained at 35C as it flowed over the muscle.  The 
ionic composition of the PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, 
NaH2PO4 1.18, MgSO4 1.17, and NaHCO3 24.0. Venular diameter was determined with an 
on-screen video micrometer.  After an initial post-surgical equilibration period of 30 
minutes, venules of two sizes, ~75 µm diameter; (“collecting”) and ~25 m diameter (“post-
capillary”) were selected for investigation in a clearly visible region of the muscle.  Venules 
selected for study had walls that were clearly visible, a brisk flow velocity, and active tone, 
as indicated by the occurrence of significant dilation in response to topical application of 10-
5 M adenosine.  All venules studied were located in a region of the muscle that was away 
from any incision.  In all experiments, at the conclusion of all procedures, 10-3 M adenosine 
and 10-3 M sodium nitroprusside were added to the superfusate to determine maximal 
diameter of the monitored venules. 
 LZR OZR 
 Animals Observations Animals Observations 
Experiment Group 1 6 6 8 8 
Experiment Group 2 12 6 12 6 
Experiment Group 3 12 6 12 6 
Experiment Group 4  6 6 8 8 
Experiment Group 5  5 5 5 5 
Total Animal Number 41 --- 45 --- 
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Experiments Group 1:  These experiments were designed to determine fundamental 
cremaster muscle venular responses to pharmacological stimuli between LZR and OZR.  
Following an equilibration period, the responses of selected venules within the cremaster 
muscle of LZR and OZR were assessed in response to increasing concentrations of 
acetylcholine (10-10 – 10-6 M), phenylephrine (α1 adrenoreceptor agonist; 10-10 – 10-6 M), 
clonidine (α2 adrenoreceptor agonist, 10-10 – 10-6 M), angiotensin II (vasoconstrictor 
peptide, 10-10 – 10-6 M), endothelin (vasoconstrictor peptide, 10-10 – 10-6 M) or 
acetylcholine (endothelium-dependent dilator, 10-10 – 10-6 M).   
Experiments Group 2:  These experiments determined basic signaling mechanisms that can 
contribute to the alterations in dilator reactivity to acetylcholine and the constrictor reactivity 
to phenylephrine determined between LZR and OZR in Group 1.  For these experiments, 
following the determination of baseline responses to acetylcholine and phenylephrine (as 
above), the cremaster muscle was treated with L-NAME (nitric oxide synthase inhibitor; 10-4 
M), indomethacin (cyclooxygenase inhibitor; 10-5 M), TEMPOL (cell-permeable antioxidant; 
10-4 M) or SQ-29548 (PGH2/TxA2 receptor antagonist, 10
-5 M).   As in our previous studies 
(Butcher et al., 2013; Frisbee et al., 2014), to exert maximum effectiveness, each inhibitor 
was applied for at least 45 minutes prior to evaluation of venular reactivity.  
 In a subset of animals from Experiment Groups 1 and 2, the cremaster muscle of LZR 
(n=10) and OZR (n=10) was treated with prazosin (α1 adrenoreceptor blocker, 10-5 M), 
yohimbine (α2 adrenoreceptor blocker, 10-5 M), or both and constrictor responses to 
norepinephrine (10-10 – 10-6 M) were determined to assess any differences in receptor 
contribution between the strains. 
Experiments Group 3:  These experiments determined basic signaling mechanisms that 
contribute to acetylcholine-induced dilation or phenylephrine-induced constriction of 
cremaster muscle venules of LZR and OZR following pretreatment with 10-4 M TEMPOL.  
Following incubation with the antioxidant, venular responses to increasing concentrations of 
acetylcholine and phenylephrine were assessed under the new “control” conditions, and 
following treatment of the muscle with L-NAME, indomethacin, or SQ-29548, as described 
above. 
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Experiment Group 4:  These experiments determined the responses of in situ cremaster 
muscle venules of LZR and OZR in response to increased metabolic demand.  Contraction of 
the cremaster muscle was evoked by three minutes of electrical field stimulation at 0.5, 1 or 3 
Hz (400 ms duration, 60 Hz within train, 7V; Grass SD 48).   At the conclusion of the muscle 
contraction period, venular diameter and center-line erythrocyte velocity (optical Doppler 
velocimeter, Texas A&M University, College Station, TX) were determined and used for the 
calculation of hyperemic responses (see below). 
Experiment Group 5:  These experiments determined the degree of leukocyte adhesion and 
rolling on the post-capillary venular endothelium between LZR and OZR.  In a separate 
cohort of LZR and OZR, the in situ extensor digitorum longus muscle was prepared as 
described previously (Frisbee et al., 2014; Tyml and Budreau, 1991).  Following 
preparation of the muscle for imaging, 10 random high magnification fields of view (Plan-
Neo 20x/0.5 and 40x/0.75; Zeiss) were recorded using a high-speed cooled digital imaging 
system (Axiocam HSm; Zeiss) for later analyses. Animals received a bolus injection of 
rhodamine 6G (0.3 mg/kg; Sigma) to permit visualization of leukocytes. Rhodamine 6G-
labeled vascular cells were visualized by epi-illumination at 510-560 nm, using a 590-nm 
emission filter. The number of rolling and adherent leukocytes in venules was expressed 
as cells/mm2 of endothelial surface, calculated from the diameter and length of the venular 
segment. Leukocytes were considered adherent if they remained stationary for a 30 second 
observation period. Leukocytes were considered rolling if their velocity was less than 250 
μm/sec (Zeintl et al., 1989). 
Histological Determination of Microvessel Density:  From LZR and OZR that were 
selected from each of the above groups, the gastrocnemius muscle from the left leg was 
removed, rinsed in PSS and fixed in 0.25% formalin.  Muscles were embedded in paraffin 
and cut into 5 µm cross sections.  Sections were incubated with Griffonia simplicifolia I 
lectin (GS-1) and dipeptidylpeptidase IV (DPEP IV), for subsequent determination of 
microvessel density.  GS-1 is a general stain that labels all microvessels <20 µm in diameter 
(Greene et al., 1990) and DPEP IV preferentially stains venular ends of capillaries 
(Mrázková et al., 1986).  Labeled microvessel density was determined using fluorescent 
(for GS-1) or light microscopy (for DPEP IV) as described previously (Frisbee et al., 2014). 
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Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-
keto-prostaglandin F1α(6-keto-PGF1α; the stable breakdown product of PGI2; Liu et al., 1997; 
Nies 1986), and 11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma 
breakdown product of TxA2; Catella et al., 1986) in response to challenge with arachidonic 
acid (10-6 M) was assessed using pooled conduit veins (e.g., femoral, saphenous) from LZR 
and OZR.  Pooled vessels from each animal were incubated in microcentrifuge tubes in 1 ml 
of physiological salt solution for 30 minutes under control conditions (21% O2 with the 
arachidonic acid challenge).  After this time, the superfusate was removed, stored in a new 
microcentrifuge tube and frozen in liquid N2, while a new aliquot of PSS with arachidonic 
acid was added to the vessels for the subsequent 30 minutes.  After the second 30 minute 
period, this PSS was transferred to a fresh tube, frozen in liquid N2 and stored at -80C.  
Metabolite release by the vessels was determined using commercially available EIA kits for 
6-keto-PGF1 and 11-dehydro-TxB2 (Cayman).  
Data and Statistical Analyses:  Blood flow in venular segments within in situ cremaster 
muscle of LZR and OZR was calculated as: 
𝑄 = (𝑉 × 1.6−1)(𝜋𝑟2)(0.001) 
where Q represents venular perfusion (nl•s-1), V represents the measured red cell velocity 
from the optical Doppler velocimeter (mm•s-1; with V/1.6 representing an estimated 
average velocity assuming a parabolic flow profile; Baker and Wayland, 1974), and r 
represents venular radius (µm; Davis, 1987).    
 All data are presented as mean±SD.  Statistically significant differences in measured 
and calculated parameters between LZR and OZR in the present study were determined using 
repeated measures analysis of variance (RM-ANOVA), where agonist concentration or 
muscle stimulation frequency were used as the repeated measures.  Statistically significant 
differences in arachidonic acid metabolite production, leukocyte adhesion/rolling and 
measures of microvessel density between LZR and OZR were assessed using standard 
ANOVA or Student’s t-test, as appropriate.  Student-Newman-Keuls post hoc test was used 
when appropriate and p<0.05 was taken to reflect statistical significance.   
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2.4 Results 
 At ~17 weeks, OZR exhibited all aspects of the metabolic syndrome, being obese as 
compared to age-matched LZR, with impaired glycemic control, dyslipidemia in both 
cholesterol and triglyceride levels, with a moderate level of hypertension (Table 2).  In 
addition, OZR exhibited both a chronic level of oxidant stress within the vasculature as well 
as a chronic state of inflammation.  Within the in situ cremaster muscle, venular diameters 
under untreated conditions demonstrated a modest reduction in diameter in OZR as compared 
to LZR, and there was no difference in venular diameter under passive conditions.   When 
taken together, however, calculated active tone of in situ venules for OZR in the post-capillary 
level, but not in the collecting venules, was elevated as compared to that for LZR. 
 
Table 2.  Baseline characteristics (mean±SD) of ~17 week old LZR and OZR used in the present study.  * p<0.05 versus LZR. 
 
 LZR OZR 
Mass (g) 35859 67971* 
MAP (mmHg) 98±21 129±35* 
[Glucose]plasma (mg/dl) 105±49 164±65* 
[Insulin]plasma (ng/ml) 1.4±1.1 7.6±6.0* 
[Cholesterol]plasma (mg/dl) 84±38 132±65* 
[Triglycerides]plasma (mg/dl) 91±53 361±118* 
[Nitrotyrosine]plasma (ng/ml) 11±16 44±36* 
[TNF-]plasma (pg/ml) 2.1±1.6 7.4±4.7* 
[MCP-1]plasma (pg/ml) 32±27 94±47* 
 Post-Capillary Venules 
Resting Diameter (m) 21±11 19±12 
Maximum/Passive Diameter (m) 36±16 37±18 
Active Tone (%) 40±17 49±17* 
 Collecting Venules 
Resting Diameter (m) 66±17 62±18 
Maximum/Passive Diameter (m) 105±21 107±24 
Active Tone (%) 37±16 42±18 
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 Figure 1 summarizes post-capillary venular dilator responses (to acetylcholine, Panel 
A) or constrictor responses (to endothelin, Panel B; angiotensin II, Panel C; clonidine, Panel 
D; or phenylephrine, Panel E).  In response to increasing concentrations of acetylcholine, 
dilator responses of both distal and proximal venules of OZR were attenuated as compared to 
responses in LZR.  Venules from OZR and LZR all demonstrated a robust constriction in 
response to increasing concentrations of endothelin, angiotensin II and clonidine (Panels B-
D), although there were no demonstrable differences in these responses between strains.  
However, venular constrictor responses to increasing concentrations of the 1 adrenoreceptor 
agonist phenylephrine were significantly increased in OZR over the mid-range of the agonist 
challenge (Panel E).   
 
Figure 1.  Data describing the reactivity of post-capillary venules within in situ cremaster muscle of LZR  and OZR in response 
to increasing concentrations of acetylcholine (Panel A), endothelin (Panel B), angiotensin II (Panel C), clonidine (Panel D) 
and phenylephrine (Panel E).  Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage 
of the initial resting state (~ 25 m).  * represents p<0.05 versus responses from LZR at that agonist concentration.  Results 
and determination of statistically significant difference represent n=6 observations from 6 animals in LZR; n=8 observations 
from 8 animals in OZR. 
 Data describing the reactivity of collecting venules within the in situ cremaster muscle 
of LZR and OZR are presented in Figure 2.  As with the smaller venules, dilator responses of 
larger collecting venules to acetylcholine were attenuated in OZR as compared to responses 
in LZR (Panel A), while responses to increasing concentrations of endothelin (Panel B) and 
angiotensin II (Panel C) were comparable.  However, while venular constrictor responses to 
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phenylephrine were enhanced in OZR as compared to LZR (Panel D), responses to clonidine 
(Panel E) were also increased versus those in LZR.     
 
Figure 2.  Data describing the reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response 
to increasing concentrations of acetylcholine (Panel A), endothelin (Panel B), angiotensin II (Panel C), clonidine (Panel D) 
and phenylephrine (Panel E).  Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage 
of the initial resting state (~ 70 m).  * represents p<0.05 versus responses from LZR at that agonist concentration. Results 
and determination of statistically significant difference represent n=6 observations from 6 animals in LZR; n=8 observations 
from 8 animals in OZR. 
 Figure 3 presents the mechanistic contributors to the venular dilation to acetylcholine 
in post-capillary venules of LZR (Panels A and C) and OZR (Panels B and D).  In LZR, dilator 
responses of venules to increasing concentrations of acetylcholine were largely nitric oxide-
dependent, as treatment with L-NAME significantly attenuated responses (Panel A).  While 
there was a contribution from cyclooxygenase products to this response, it was less substantial 
than that for nitric oxide.   In OZR, the attenuated venular dilation to acetylcholine was 
abolished following treatment of the cremaster muscle with L-NAME, but only minimally 
impacted as a result of treatment with indomethacin.  However, incubation of the tissue with 
TEMPOL resulted in a more robust dilation to increasing concentrations of acetylcholine 
(Panel B).   If the cremaster muscle of LZR or OZR was incubated with TEMPOL prior to 
challenge with increasing concentrations of acetylcholine, these relationships were not 
fundamentally altered in venules of LZR (Panel C).  However, the improvement in the 
acetylcholine-induced venular dilation in OZR was abolished by L-NAME, unaffected by 
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indomethacin, and mildly improved by blockade of PGH2/TxA2 receptors with SQ-29548 
(Panel D). 
   
Figure 3.  The dilator reactivity of post-capillary venules within in situ cremaster muscle of LZR and OZR in response to 
increasing concentrations of acetylcholine (Panels A and B, respectively).  Data are presented for venular reactivity under 
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or 
TEMPOL.  For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals 
in OZR.  Also presented are data describing the reactivity of post-capillary venules following pre-treatment with TEMPOL in 
LZR and OZR (Panels C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, 
indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to 
reactivity.  Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage of the initial resting 
state (~ 25 m).  * represents p<0.05 versus responses from LZR at that agonist concentration.  For Panels C and D, results 
represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals in OZR.  All statistical analyses were 
done on the number of observations within the group, not the number of animals within the group.   Please see text and Table 
1 for details. 
The relationships between acetylcholine-induced dilation (with or without pre-
treatment with TEMPOL) and its basic mechanistic contributors were consistent in the larger 
collecting venules within in situ cremaster muscle of LZR and OZR with some exceptions 
(Figure 4, Panels A-D).  In post-capillary venules from LZR and OZR rats and in collecting 
venules from OZR, indomethacin did not have a demonstrable impact on dilator responses 
to acetylcholine, but significantly attenuated collecting venular dilation in LZR.  Further, 
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the indomethacin-sensitive component of the collecting venular dilation to acetylcholine 
was absent in OZR and in LZR and OZR pre-treated with TEMPOL. 
 
Figure 4.  The dilator reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to 
increasing concentrations of acetylcholine (Panels A and B, respectively).  Data are presented for venular reactivity under 
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or 
TEMPOL.  For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals 
in OZR.   Also presented are data describing the reactivity of collecting venules following pre-treatment with TEMPOL to 
normalize responses in OZR (Panels C and D, respectively), where the cremaster muscle was subsequently treated with L-
NAME, indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or 
PGH2/TxA2 to reactivity.  Data are presented as the mean±SD change in venular inner diameter, expressed as a percentage of 
the initial resting state (~ 70 m).  * represents p<0.05 versus responses from LZR at that agonist concentration.  For Panels 
C and D, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals in OZR. All statistical 
analyses were done on the number of observations within the group, not the number of animals within the group.   Please see 
text and Table 1 for details. 
 Using prazosin (1 adrenergic receptor blocker) and yohimbine (2 adrenergic 
receptor blocker), alone and in combination, the constrictor responses of post-capillary and 
collecting venules within cremaster muscle of LZR and OZR in response to increasing 
concentrations of norepinephrine were demonstrated to be almost entirely 1-receptor-
dependent in postcapillary venules and predominantly 1-receptor dependent (with a smaller 
contribution from 2 adrenergic receptors) in collecting venules in both strains (data not 
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shown).  Data describing the interaction of altered endothelial function and the venular 
constriction to increasing concentration of norepinephrine are summarized in Figure 5.  In the 
immediate post-capillary venules, treatment of the cremaster muscle with L-NAME increased 
constrictor responses to norepinephrine in LZR (Panel A), but was without effect in OZR 
(Panel B).   While treatment with indomethacin was largely without effect in either strain, 
treatment of the muscle with TEMPOL had only a minor effect on venular responses in LZR, 
but attenuated the constrictor response in OZR venules.  Following pre-treatment of the 
cremaster muscle with TEMPOL in LZR, responses to increasing concentrations of 
norepinephrine and the impact of L-NAME, indomethacin and SQ-29548 were similar to that 
determined under untreated conditions (Panel C).  In contrast, pre-treatment of the cremaster 
muscle of OZR with TEMPOL (moderating the severity of the norepinephrine-induced 
constriction), shifted venular reactivity such that constrictor responses were increased 
following treatment with L-NAME, were unaffected by indomethacin, but were reduced 
following additional treatment with SQ-29548 (Panel D).  Comparable to the responses to 
acetylcholine challenge, these relationships between norepinephrine-induced venular 
constriction (with or without pre-treatment with TEMPOL) and its basic contributors were 
similar in the collecting venules within in situ cremaster muscle of LZR and OZR (Figure 6, 
Panels A-D). 
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Figure 5.  The constrictor reactivity of post-capillary venules within in situ cremaster muscle of LZR and OZR in response to 
increasing concentrations of norepinephrine (Panels A and B, respectively).  Data are presented for venular reactivity under 
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or 
TEMPOL.  For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals 
in OZR.   Also presented are data describing the reactivity of post-capillary venules following pre-treatment with TEMPOL 
(Panels C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) 
or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to reactivity.  Data are 
presented as the mean (±SD) change in venular inner diameter, expressed as a percentage of the initial resting state (~ 25 m).  
* represents p<0.05 versus responses from LZR at that agonist concentration.  For Panels C and D, results represent n=6 
observations from 12 animals in LZR; n=6 observations from 12 animals in OZR.  All statistical analyses were done on the 
number of observations within the group, not the number of animals within the group.   Please see text and Table 1 for details. 
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Figure 6.  The constrictor reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to 
increasing concentrations of norepinephrine (Panels A and B, respectively).  Data are presented for venular reactivity under 
untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or 
TEMPOL.  For Panels A and B, results represent n=6 observations from 12 animals in LZR; n=6 observations from 12 animals 
in OZR.   Also presented are data describing the reactivity of collecting venules following pre-treatment with TEMPOL (Panels 
C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) or SQ-
29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH2/TxA2 to reactivity.  Data are presented as 
the mean (±SD) change in venular inner diameter, expressed as a percentage of the initial resting state (~ 70 m).  * represents 
p<0.05 versus responses from LZR at that agonist concentration.  For Panels C and D, results represent n=6 observations from 
12 animals in LZR; n=6 observations from 12 animals in OZR.  All statistical analyses were done on the number of 
observations within the group, not the number of animals within the group.   Please see text and Table 1 for details. 
 In response to field stimulation of the in situ cremaster muscle of LZR and OZR at 
increasing metabolic demand, the dilator and perfusion responses of post-capillary and 
collecting venules are summarized in Figure 7.  In response to increasing metabolic demand, 
the dilator responses of post-capillary (Panel A) and collecting (Panel B) cremaster muscle 
venules was attenuated at the low (0.5 Hz) and moderate (1.0 Hz) contraction frequencies, but 
was similar at the high (2.0 Hz) contraction frequency.  Perfusion responses followed a similar 
pattern, exhibiting a restrained hyperemic response at the lower two contraction frequencies 
in both post-capillary (Panel C) and collecting (Panel D) venules, that was not present at the 
high contraction frequency. 
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Figure 7.  The responses of venules within in situ cremaster muscle of LZR and OZR in response to increasing metabolic 
demand, imposed via field stimulation across the muscle.  Dilator responses to elevated metabolic demand are presented for 
post-capillary and collecting venules in Panels A and B, respectively; while functional hyperemic responses are presented in 
Panels C and D, respectively.  Data (mean±SD) are presented for venular responses, expressed as a percentage of values at the 
initial resting state. * represents p<0.05 versus responses from LZR at that stimulation frequency. Results represent n=6 
observations from 6 animals in LZR; n=8 observations from 8 animals in OZR. All statistical analyses were done on the 
number of observations within the group, not the number of animals within the group.   Please see text and Table 1 for details. 
 Pre-treatment of the cremaster muscle with TEMPOL moderated this difference in 
metabolism-induced venular dilation in the post-capillary venules of OZR, but had no 
significant effect on the dilator responses to muscle contraction in the larger collecting venules 
(Figure 8, Panels A and B).  A similar impact was determined on blood flow responses, where 
hyperemia was improved in both venular diameter ranges, although responses in the larger 
venules failed to achieve statistical significance (Panels C and D).  In contrast, pre-treatment 
of the cremaster muscle with phentolamine (1/2 adrenoreceptor blocker) had minimal 
impact on contraction-induced dilation or perfusion in post-capillary venules (Panels A and 
C), although both the dilator and hyperemic responses were improved in the larger collecting 
venules (Panels B and D).   
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Figure 8.  The responses of venules within in situ cremaster muscle of LZR and OZR in response to increasing metabolic 
demand, imposed via field stimulation across the muscle.  Dilator responses to elevated metabolic demand are presented for 
post-capillary and collecting venules in Panels A and B, respectively; while functional hyperemic responses are presented in 
Panels C and D, respectively.  Data (mean±SD) are presented under control conditions for each strain, and following pre-
treatment of the cremaster muscle (from OZR only) with TEMPOL or phentolamine.  All data are expressed as a percentage 
of values at the initial resting state.  * represents p<0.05 versus responses from LZR at that stimulation frequency.  Results 
represent n=6 observations from 6 animals in LZR; n=8 observations from 8 animals in OZR.  All statistical analyses were 
done on the number of observations within the group, not the number of animals within the group.   Please see text and Table 
1 for details. 
 The venous production of PGI2 and TxA2 in response to challenge with arachidonic 
acid is summarized in Figure 9.  Venous PGI2 production, estimated from the levels of 6-keto-
PGF1, was reduced in OZR as compared to levels in LZR under control conditions (Panel 
A).  Pre-treatment of the pooled veins with TEMPOL had no effect on responses in LZR, but 
resulted in an increase in the production of PGI2 in OZR.   In contrast, venous production of 
TxA2, estimated from the levels of 11-dehydro-TxB2, was elevated in OZR vs. LZR under 
control conditions (Panel B), but was reduced toward levels determine in LZR following pre-
treatment of veins with TEMPOL.  Venous production of either PGI2 or TxA2 was abolished 
following treatment of the vessels with indomethacin.   
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Figure 9.  Venous production of 6-keto-PGF1 (from PGI2; Panel A) and 11-dehydro-TxB2 (from TxA2; Panel B) following 
challenge with arachidonic acid in pooled vessels from LZR and OZR. Data (mean±SD) are presented under control conditions 
for each strain, and following pre-treatment of the pooled vessels with either TEMPOL or indomethacin (INDO).  * represents 
p<0.05 versus responses from LZR within the treatment group.  Results represent n=6 observations from 6 animals in LZR; 
n=6 observations from 6 animals in OZR.   All tissues for these ex vivo experiments were taken from animals within 
Experimental Groups 1 and 2.  Please see text for details. 
 Data describing the adhesion and rolling of leukocytes in the post-capillary venules of 
the in situ extensor digitorum longus muscle of LZR and OZR are summarized in Figure 10.  
For both adhesion of leukocytes and rolling of adherent cells, responses were increased in the 
networks of OZR as compared to that for LZR. 
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Figure 10.  Data describing the adhesion and rolling of leukocytes in the post-capillary venules of in situ extensor digitorum 
longus muscle of LZR and OZR.  Rhodamine 6G-labeled vascular cells were visualized by epi-illumination and the number 
of rolling and adherent leukocytes in venules was expressed as number of cells/are of endothelial surface, calculated from the 
diameter and length of the venular segment.  * represents p<0.05 vs. LZR.  Results represent n=5 observations from 5 animals 
in LZR; n=5 observations from 5 animals in OZR.  Please see text for details. 
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 Figure 11 presents data describing microvessel and post-capillary venular density 
within skeletal muscle of OZR and LZR.  In both cases, microvascular and post-capillary 
venular density were significantly reduced in OZR as compared to levels in age-matched 
LZR.   
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Figure 11.  The change in skeletal muscle microvessel density in LZR and OZR.  Results are presented following 
tissue staining with Griffonia simplicifolia 1 lectin (GS-1 lectin; for general microvessel density) or dipeptidylpeptidase 
IV (DPEP IV; for the post-capillary venular ends of capillaries).  Data are presented as mean±SD, n=8 for both strains 
of rats.  * represents p<0.05 vs. LZR.  Results represent n=8 observations from 8 animals in LZR; n=8 observations 
from 8 animals in OZR.   All tissues for these ex vivo experiments were taken from animals within Experimental 
Groups 1 and 2.  Please see text for details. 
 
2.5 Discussion 
To date, studies elucidating the impact of the metabolic syndrome on vascular regulation have 
focused on arterial/arteriolar control. However, the arterial/arteriolar dysregulation observed 
in the metabolic syndrome are (at least partially) a result of a pro-oxidant, pro-inflammatory 
and pro-thrombotic environment, conditions which are known to also impact the 
venular/venous side of the circulation. In an effort to provide a foundation from which more 
targeted investigation can be directed, the present study investigated the impact of the 
metabolic syndrome on skeletal muscle venular function at two levels (post-capillary and 
collecting venules.  Further, it was recently suggested that the pro-inflammatory and pro-
oxidant conditions observed in post-capillary venules may be the initiating site for 
microvascular rarefaction that is commonly associated with chronic metabolic disease 
(Clough, 2015; Frisbee et al., 2014; Gilbert, 2013) and that fluid handling across the 
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microcirculation may be altered by chronic impairments to glycemic control (Huxley and 
Scallan, 2011; Scallan et al., 2015).   
 In the present study, impaired acetylcholine-induced venular dilation in OZR 
appeared to be a result of elevated oxidative stress on venular nitric oxide bioavailability, as 
treatment of the cremaster muscle with the antioxidant TEMPOL partially restored venular 
function to that determined in LZR.  While this is consistent with data determined in multiple 
organs (Tune et al., 2017) and across arterial/arteriolar levels (Goodwill and Frisbee, 2012), 
these data are critical for our understanding of both capillary handling of erythrocytes as well 
as fluid exchange across the microcirculation.  Interestingly, there appears to be a role for an 
increased arachidonic acid-induced production of TxA2 in the loss of normal endothelium-
dependent dilator reactivity, which is likely associated with the chronic pro-inflammatory 
condition observed in OZR.  While this increase in TxA2 can have multiple effects, including 
impacting leukocyte adhesion (Morris et al., 2009; Tole et al., 2010; Totani et al., 2012) and 
venular reactivity and responses, this also may represent a mechanism for modifying fluid 
filtration/absorption across the capillary networks under settings of chronic metabolic disease 
(Huxley and Scallan, 2011; Scallan et al., 2015) as well as contributing to the genesis of the 
microvessel rarefaction discussed above (Frisbee et al., 2014).  
 Similar to arteries and arterioles, the sympathetic nervous system is a major 
regulator of venous and venular tone, with sympathetic nerve fibers directly innervating α1 
and α2 adrenoreceptors on vascular smooth muscle cells (Mellander and Lewis, 1963; 
Tabrizchi and Pang, 1992; van Brummelen et al., 1986).   However, in contrast to arterioles, 
increased sympathetic nerve activity to small veins and venules results in a reduction in 
vascular compliance, thus altering venous volume (capacitance) with comparatively less 
impact on systemic resistance (Rothe, 1983).  Although outside of the scope of the present 
study, recent work has also demonstrated that a neuropeptide Y (NPY) -induced 
constriction of veins in humans suggest that, in addition to α1- and α2-adrenoreceptor 
mediated control, sympathetic activity can modify venous or venular tone through NPY 
Y1 receptor activation (Luu et al., 1992; Pongor et al., 2010).  
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 The results from the present study suggest that venular reactivity to adrenergic stimuli 
was elevated in OZR vs. LZR, with this effect being predominantly mediated via the 1 
adrenoreceptor, but with an apparent role for the 2 adrenoreceptor as well in the larger 
collecting venules.    While there appeared to be a contribution to this effect mediated via the 
impaired endothelial function, it was not clear that these contributions, whether mediated via 
a loss of nitric oxide bioavailability or an increase in venular levels of TxA2 were significant 
contributors to the altered tone regulation.  However, it was clear this represented an alteration 
to adrenergic signaling itself, and not a broad-spectrum shift in venular constrictor reactivity 
at either the post-capillary or collecting venular level of the microcirculation.   
 The alterations to venular reactivity between LZR and OZR take on additional 
significance when evaluated in response to metabolic challenge.  Increasing metabolic 
demand, instigated via electrical field stimulation of the cremaster muscle at increasing 
frequency (McKay et al., 1998; Saito et al., 1994), resulted in a functional dilator and 
hyperemic response in OZR that was restrained in comparison to that determined in LZR, 
with the exception of the highest frequency of stimulation (3 Hz; where responses between 
LZR and OZR venules were comparable).   
 Previous work by Hester’s group has implicated the venular release of prostacyclin 
(PGI2), as a contributing mechanism to the dilation of the adjacent arterioles that perfuse the 
capillary network under conditions of elevated metabolic demand in skeletal muscle (Hester 
and Hammer, 2002; McKay et al., 1998; Saito et al., 1994).  Further, it has also been 
established that, under conditions of high oxidant stress and inflammation, the production of 
PGI2 can be shifted to TxA2 (Zou. 2007), and that there is an increased arterial (Butcher et al., 
2013; Goodwill et al., 2008; Xiang et al., 2006) and venous (above) production of TxA2 in 
OZR manifesting the metabolic syndrome.  Speculatively, it may be that the negative impact 
of vascular production of TxA2 on muscle perfusion that has been demonstrated previously 
may partially be of venular origin, impacting not only its own reactivity, but also the caliber 
of adjacent resistance arterioles leading into the microcirculation and contributing to the loss 
in overall system flexibility and adaptive potential to imposed challenges (Frisbee et al., 2016; 
Hester and Hammer, 2002).  This speculation requires further investigation.   
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 As has been well established, the venular circulation is a low pressure “collecting 
network” for the output of the high pressure “distribution network” of arteriolar perfusion 
through the capillaries.  While the increased adrenergic reactivity and impaired endothelial 
function can serve to increase venular tone, the extent to which this shift in function acts to 
increase perfusion resistance across the microcirculation is unclear at this time and will require 
additional investigation.  However, given the observation of an increased leukocyte adhesion 
to the venular endothelium, this physical blockade has been previously demonstrated to 
increase perfusion resistance within those regions (Harris et al., 1994; Harris and Skalak, 
1993; Lipowsky et al., 1988) through the establishment of regions of “low radius” that are 
no longer functionally able to effectively regulate diameter.  From the perspective of mass 
transport and exchange, the extent to which an increase in venular tone is sufficient to elevate 
resistance downstream from the capillaries is unclear.  From a network perspective, it is 
reasonable to postulate that alterations in venular function may contribute to erythrocyte 
distribution heterogeneity and lowered microvascular hematocrit previously reported in OZR 
(Butcher et al., 2014).   
 An obvious implication for the increase in venular resistance would also be an increase 
in the intravascular pressure within the venular environment, leading to an increased net fluid 
filtration into the tissue across the microcirculation.  Recent study by Scallan et al. (2015) may 
provide insight into this outcome as the loss of nitric oxide bioavailability in the lymphatic 
vessels of diabetic mice (where vascular nitric oxide levels have also been established to be 
impaired) results in a release on the inhibition of phosphodiesterase 3 (PDE3), compromising 
lymphatic integrity and increasing tissue edema.  It will be intriguing to determine if this 
fascinating observation on fluid handling across the microcirculation in diabetes represents 
multiple contributing pathways involving impaired venular function as well. 
 In summary, with the development of the metabolic syndrome, venular function 
within the skeletal muscle of OZR is impaired at both the post-capillary and collecting venular 
segments.  Along with an impaired endothelium dependent dilation, and a modest increase in 
adrenergic constriction, the combination of a significant elevation in TxA2 production may 
act to impair functional dilator and hyperemic responses at the venular level, and may 
contribute to the impaired function at the adjacent arteriolar level as well (Hester and Hammer, 
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2002).  The implications of this shift in skeletal muscle venular function with the development 
of the metabolic syndrome on issues such as aggregate microvascular perfusion resistance, 
mass transport and exchange within with capillary networks, and fluid handling across the 
microcirculation are compelling avenues for future interrogation. 
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3.1 Abstract 
Purpose: Although studies suggest elevated adrenergic activity paralleling metabolic 
syndrome in obese Zucker rats (OZR), the moderate hypertension and modest impact on 
organ perfusion questions the multi-scale validity of these data.  Methods: To understand 
how adrenergic function contributes to vascular reactivity in OZR, we utilized a multi-
scale approach to investigate pressure responses, skeletal muscle blood flow and vascular 
reactivity following adrenergic challenge.  Results: For OZR, adrenergic challenge 
resulted in increased pressor responses vs. lean Zucker rats (LZR); mediated via 1 
receptors, with minimal contribution by either ROS or NO bioavailability.  In situ 
gastrocnemius muscle of OZR exhibited blunted functional hyperemia, partially restored 
with 1 inhibition, although improved muscle performance and VO2 required combined 
treatment with TEMPOL. Within OZR in situ cremaster muscle, proximal arterioles 
exhibited a more heterogeneous constriction to adrenergic challenge, biased toward 
hyperresponsiveness, vs. LZR.  This increasingly heterogeneous pattern was mirrored in 
ex vivo arterioles, mediated via 1 receptors, with roles for ROS and NO bioavailability 
evident in hyperresponsive vessels only.  Conclusions: These results support the central 
role of the 1 adrenoreceptor for augmented pressor responses and elevations in vascular 
resistance but identify an increased heterogeneity of constrictor reactivity in OZR that is 
presently of unclear purpose. 
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List of Abbreviations 
 
LZR: lean Zucker rat 
OZR: obese Zucker rat 
PRZ: prazosin 
PHT: phentolamine 
YOH: yohimbine 
ROS: reactive oxygen species 
NO: nitric oxide 
PVD: peripheral vascular disease 
TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1 -oxyl 
L-NAME: L-NG-Nitroarginine methyl ester  
PSS: physiological salt solution 
VO2: oxygen uptake  
Q: muscle blood flow 
CaO2: arterial oxygen content 
CvO2: venous oxygen content 
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3.2 Introduction 
 As has been well established, the development of peripheral vascular disease (PVD) 
risk factors of sufficient severity can lead to profound alterations in the ability of resistance 
vessels to regulate their degree of tone, and thus the levels of perfusion to and within the 
tissues and organs they serve (17).  Multiple previous studies across laboratories have 
implicated alterations to vascular nitric oxide (NO) bioavailability and effectiveness (3), 
altered arachidonic acid metabolism and the ensuing impacts on vascular tone (7, 15), the 
impacts of reactive oxygen species (ROS; 13, 19), myogenic activation (16, 23, 28) and 
alterations mediated via adrenergic signaling and vascular reactivity (1, 6, 21).  However, 
it is unclear that conclusions from previous studies on the impact of altered adrenergic 
signaling/responses represent an accurate reflection of the true alterations to the integrated 
system of microvascular perfusion and control within the setting of elevated PVD risk. 
 The metabolic syndrome is a multi-pathology state represented by the combined 
presentation of multiple risk factors for PVD, including obesity, impaired glycemic control, 
atherogenic dyslipidemia, and moderate hypertension; with the additional systemic 
outcomes of a pro-oxidant, pro-inflammatory and pro-thrombotic state (4, 18).    Arguably 
the most important outcome of this condition is that it results in the impairment of perfusion 
(both bulk perfusion and the spatial-temporal matching of perfusion with metabolic 
demand) in the tissues and organs of the afflicted subject (8, 12). Previous studies have 
provided compelling evidence that adrenergic traffic (5), adrenergic signaling (21) and 
adrenergic vascular responses (9) may all be elevated within the metabolic syndrome (the 
setting for elevated PVD risk).  Further, it can clearly be demonstrated that treatment of 
the moderate hypertension within metabolic syndrome in the obese Zucker rat (OZR) 
model with prazosin (50 µg/kg) not only abolishes the elevated blood pressure that 
develops within this state, it can equalize blood pressure characteristics to those determined 
in the control strain, the lean Zucker rat (LZR, 27).  However, what is unclear at this point 
is how a general elevation in vascular adrenergic output with the potential for multiple 
contributing elements, producing significant elevations in vascular resistance, functions 
within the in vivo setting to produce the relatively mild/moderate elevations in arterial 
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pressure that have been determined (9, 29).  Clearly, we have not arrived at an accurate 
understanding of adrenergic control over muscle perfusion in the OZR model. 
 The purpose of the present study was to employ a multi-scale approach, integrating 
in vivo, in situ, and ex vivo conditions to garner a more accurate understanding of the 
changes in adrenergic control that are implicit for the development of skeletal muscle 
microvasculopathy within the metabolic syndrome.  In vivo approaches will incorporate 
whole animal pressor responses with hindlimb blood flow measurements in anesthetized 
animals, while in situ approaches will employ perfusion/muscle performance relationships 
for gastrocnemius muscle and direct microscopic evaluation of vascular reactivity in 
cremaster muscle, and ex vivo approaches will employ studies of isolated vascular 
responses under specific challenged states.  Taken together, these data will allow for a more 
accurate understanding of adrenergic function in the control of muscle blood flow in OZR 
will the full manifestation of the metabolic syndrome. 
3.3 Materials and Methods 
Animals: Male LZR (n=27) and OZR (n=45) were delivered at 6-7 weeks of age, and after 
one week of acclimation to the local environment, were aged to ~17 weeks for final 
experiment usage.  All animals were used between 16 and 18 weeks of age.  Animals were 
fed standard chow and tap water ad libitum for all experiments unless otherwise noted.   
Animals were housed in an accredited animal care facility, and all protocols received prior 
IACUC approval from the West Virginia University.  At ~17 weeks of age, each rat was 
anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and all rats received 
tracheal intubation to facilitate maintenance of a patent airway.  In all rats a carotid artery and 
an external jugular vein were cannulated for determination of arterial pressure and for 
intravenous infusion of additional substances as necessary (e.g., anesthetic, heparin, etc.).  In 
addition, an aliquot of mixed venous blood was drawn from the jugular vein cannula for a full 
profiling of metabolic and endocrine biomarkers (see below). 
Experimental Series #1:  In Vivo Whole Pressor Responses: Following the initial surgical 
preparation (above), the femoral artery was isolated midway between the femoral triangle and 
the knee and a perivascular blood flow probe was placed around the vessel (Transonic 0.7V) 
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which was held in place via a micromanipulator.  After a period of equilibration, each animal 
was challenged with an intravenous infusion of the -adrenoreceptor agonist 
norepinephrine (10 µg/kg), with pressor responses and hindlimb blood flow continuously 
recorded.  Subsequently, rats received a bolus intravenous infusion of the α1 adrenoreceptor 
antagonist prazosin (1 mg/kg), the α2 adrenoreceptor antagonist yohimbine (5 mg/kg), or the 
α1/α2 adrenoreceptor antagonist phentolamine (10 mg/kg), each followed by 30 minutes of 
equilibration, in order to remove different components of adrenergic tone from the system 
(n=5 for each antagonist; total n=15 for each strain).  After a second norepinephrine challenge 
with the respective antagonist present, animals were treated with bolus intravenous infusions 
of TEMPOL (50 mg/kg) and a final subsequent treatment with L-NAME (100 mg/kg) to 
assess the roles of reactive oxygen species and nitric oxide bioavailability in contributing to 
responses following adrenergic challenge.  After treatment with TEMPOL and again after the 
treatment with L-NAME, a new challenge with norepinephrine was performed as described 
above.  Alterations in mean arterial pressure and femoral artery perfusion were monitored 
following agonist infusion in order to determine peak responses and the restoration of baseline 
(pre-treatment) conditions.  All infused intravenous doses of drugs were corrected for 
differences in circulating blood volume between LZR and OZR at this age (10, 24). 
Experimental Series #2:  In Situ Skeletal Muscle Perfusion:  In a separate cohort of LZR 
and OZR (n=5 for LZR; n=15 for OZR), the left gastrocnemius muscle was isolated in situ 
as fully described previously (9).  Subsequently, a perivascular flow probe (Transonic 0.5V 
or 0.7V) was placed around the femoral artery, immediately proximal to its entry into the 
muscle group, in order to measure blood flow to the gastrocnemius muscle.  At the conclusion 
of these procedures, an angiocatheter (24 gauge) was inserted into the femoral vein to allow 
for sampling of venous blood from the contracting muscle to determine blood gas levels (done 
using a Corning Rapid Lab Blood Gas Analyzer).  The preparation was covered in PSS-
soaked gauze and plastic film to minimize evaporative water loss and was placed under a heat 
lamp to maintain temperature at 37C.  At this time, heparin (500 IU/kg) was infused via the 
jugular vein to prevent blood coagulation.   
 Upon completion of the surgical preparation, the gastrocnemius muscle was 
stimulated to perform (via the sciatic nerve) bouts of isometric twitch contractions (4 Hz, 0.4 
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ms duration, 5V) lasting for 3 minutes followed by 15 minutes of self-perfused recovery time, 
with arterial pressure and femoral artery blood flow continuously monitored.   Following the 
initial contraction regimen under control conditions, rats were given an intravenous injection 
of either prazosin (1 mg/kg; n=5), phentolamine (5 mg/kg; n=5) or yohimbine (5 mg/kg; n=5) 
and the contraction regimen was repeated.  Each animal was treated with only one 
adrenoreceptor antagonist.  As above, following treatment of the animal with either 
adrenoreceptor antagonist, animals were treated with TEMPOL and L-NAME as described 
above and the contraction regimen was repeated with all data and blood collection also 
repeated as described above. 
Experiment Series #3: In Situ Skeletal Muscle Arterioles: In a dedicated cohort of rats 
(n=7 for LZR; n=15 for OZR), the left cremaster muscle was prepared for television 
microscopy (9).  After completion of the preparation, the cremaster muscle was superfused 
with PSS, equilibrated with a gas mixture containing 5% CO2 and 95% N2, and maintained at 
35C as it flowed over the muscle.  The ionic composition of the PSS was as follows (mM): 
NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 1.18, MgSO4 1.17, and NaHCO3 24.0. Arteriolar 
diameter was determined with an on-screen video micrometer.  After an initial post-surgical 
equilibration period of 30 minutes, proximal (~75 µm diameter) and distal arterioles (~30 m 
diameter) were selected for investigation in a clearly visible region of the muscle.  Arterioles 
chosen for study had walls that were clearly visible, a brisk flow velocity, and active tone, as 
indicated by the occurrence of significant dilation in response to topical application of 10-5 M 
adenosine.  All arterioles that were studied were located in a region of the muscle that was 
away from any incision.   
 Following an equilibration period, the responses of selected arterioles within the 
cremaster muscle of LZR and OZR were assessed in response to increasing concentrations 
of norepinephrine (10-10 – 10-5 M) or phentolamine (10-10 – 10-5 M), as described above, to 
establish baseline reactivity to increasing adrenergic receptor activation and inhibition, 
respectively.   As above, following washout, the cremaster muscle was treated with 
TEMPOL by adding it to the superfusate (10-4 M), and the challenge with increasing 
concentrations of norepinephrine and phentolamine was repeated.  Finally, the TEMPOL-
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treated cremaster muscle was also treated with L-NAME (10-4 M; in the superfusate) and 
challenge with the adrenergic agonist and antagonist was repeated.       
Experiment Series #4: Ex Vivo Isolated Skeletal Muscle Resistance Arterioles: In 
anesthetized rats, prior to the preparation of the cremaster muscle (above), the 
intramuscular continuation of the right gracilis artery was identified, it’s in vivo diameter 
determined using an eyepiece micrometer, and the vessel was surgically removed.  In LZR, 
arteriolar diameter estimated using this method was 1054 µm, while in OZR, the value 
was reduced to 984 µm.  Arterioles were placed in a heated chamber (37C) that allowed 
the vessel lumen and exterior to be perfused and superfused, respectively, with 
physiological salt solution (PSS; equilibrated with 21% O2, 5% CO2; 74% N2) from 
separate reservoirs.  Vessels were cannulated at both ends and were secured to inflow and 
outflow pipettes connected to a reservoir perfusion system allowing intralumenal pressure 
and lumenal gas concentration to be controlled.  Vessel diameter was measured using 
television microscopy and an on-screen video micrometer. Arterioles were extended to 
their in situ length and were equilibrated at ~80% of the animal's mean arterial pressure 
(~80 mmHg for LZR, ~100 mmHg for OZR).  Active tone for vessels in the present study, 
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to 
Ca2+-free PSS, and Dmax is the maximum diameter measured at the equilibration pressure 
in Ca2+-free PSS, averaged 333% in LZR and 353% in OZR.  To get a more accurate 
presentation of the impact of altered adrenergic function on microvascular perfusion, we 
elected to reduce the inclusion criteria for isolated arterioles in this study.  Traditionally, 
three criteria are employed to assess the viability of an individual vessel: 1) active tone 
>25%, 2) robust constrictor response to challenge with phenylephrine, 3) viable endothelial 
layer (dilator response to pharmacological challenge such as methacholine).  However, as 
one of the inclusion criteria represent the key outcome variable of the present study, this 
has the potential to cause experimental bias in terms of which vessels get included into 
experiments/analyses and which vessels are omitted for failing to achieve all three criteria.  
For the purposes of the present study, we omitted criterion #2 and simply considered 
vessels with sufficient active tone and viable endothelial function as having met the 
inclusion requirements. 
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 Prior to subsequent evaluation of arteriolar reactivity, the in vivo diameter of vessels 
was restored through addition of low levels of norepinephrine to the vessel chamber.  This 
process required ~310-10 M norepinephrine in vessels from OZR.  While vessels from 
LZR usually regained their in vivo diameter without treatment with norepinephrine (n=12), 
some vessels required a maximum norepinephrine concentration of ~110-10 M (n=3).   
Following an equilibration period, arteriolar constriction was assessed in response to 
increasing concentrations of phenylephrine (10-10 M – 10-5 M) or clonidine (10-10 M – 10-5 
M) to establish baseline reactivity to α1- and α2-adrenoreceptor agonists, respectively.   
Subsequently, reactivity of these isolated arterioles from LZR and OZR was assessed 
following treatment of the vessel with TEMPOL (10-4 M), and following incubation with 
L-NAME (10-4 M) to the TEMPOL-treated vessel.   
Data and Statistical Analyses:  In all cases, p<0.05 was taken to reflect statistical significance.  
All data are presented as mean±SE. 
In Vivo Pressor Response Experiments:  All arterial pressure, hindlimb blood flow, and 
calculated hindlimb vascular resistance (pressure/flow) data are presented as the change in the 
parameter following treatment or challenge (Δ mmHg, Δ ml/g/min, Δ mmHg/(ml/g/min), 
respectively). 
Vascular Reactivity Experiments: Arteriolar constrictor responses following challenge with 
adrenergic agonists or antagonists were fit with a three-parameter logistic equation: 

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where y  represents the change in arteriolar diameter, “min” and “max” represent the lower 
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist 
concentration, x  is the logarithm of the agonist concentration and 50log ED  represents the 
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between the 
lower and upper bounds. Statistically significant differences in lower bound employed 
ANOVA followed by Student-Newman-Keuls-test post-hoc as appropriate.  Statistically 
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significant differences in the distribution of adrenergic responses between LZR and OZR 
utilized Student’s t-test for mean and variance. 
 For the purposes of categorizing arteriolar responses to adrenergic challenge into 
“high’, “normal”, and “low” responders, the reactivity of all vessels (both OZR and LZR) 
was compared to mean responses in LZR.  Given the degree of heterogeneity in the 
responses in OZR, a value of 20% was used as the threshold for inclusion into the “high” 
or “low” responder categories.   
In Situ Gastrocnemius Muscle Experiments:  Muscle blood flow data were normalized to 
gastrocnemius muscle mass, which did not differ between LZR (2.290.08 g) and OZR 
(2.250.09 g).  Muscle oxygen uptake (VO2) was calculated using the Fick equation: 
𝑉𝑂2 = 𝑄 ×  (𝐶𝑎𝑂2 − 𝐶𝑣𝑂2) 
where Q represents blood flow, CaO2 represents arterial oxygen content and CvO2 
represents venous oxygen content.  Muscle fatigue curves were fit using a semi-logarithmic 
relationship and the slope (β) coefficient was determined using curve fitting techniques.  
Differences in muscle blood flow, O2 extraction, VO2 and the slope coefficient describing 
muscle fatigue curves of contraction were determined using ANOVA, with Student-
Newman-Keuls-test post-hoc as appropriate.   
 
 
 
 
 
 69 
 
3.4 Results 
 As summarized in Table 1, ~17 week old OZR demonstrated the full complement of 
the metabolic syndrome.  This included obesity, impaired glycemic control, dyslipidemia and 
moderate hypertension.  In addition, OZR also demonstrated a high level of chronic oxidant 
stress and inflammation, with elevated levels of nitrotyrosine and TNF-, respectively.  
Table 1.  Baseline characteristics of 17-week-old LZR and OZR used in the present study.  * p<0.05 versus LZR. 
 
 Table 2 presents the initial conditions for the vascular/systemic phenotypes across the 
conditions of the present study.  In these data, blockade of the 1 adrenergic system was 
effective in blunting the development of hypertension in OZR, as well as many of the vascular 
diameter and perfusion responses system.  Further, the impact altering the vascular NO 
bioavailability in OZR in terms of contributing to integrated vascular function was relatively 
modest compared to the impact of alterations to adrenergic function.  
 
 
 
 
 
 LZR OZR 
Mass (g) 35811 67912* 
MAP (mmHg) 98±4 129±6* 
[Glucose]plasma (mg/dl) 105±9 164±11* 
[Insulin]plasma (ng/ml) 1.4±0.2 7.6±1.0* 
[Cholesterol]plasma (mg/dl) 84±7 132±11* 
[Triglycerides]plasma (mg/dl) 91±10 361±20* 
[Nitrotyrosine]plasma (ng/ml) 11±3 44±6* 
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Table 2.  Baseline hemodynamic characteristics of 17 week-old LZR and OZR used in the present study under control 
conditions and in response to the different interventional treatments.  AMP: mean arterial pressure (mmHg); QFEM: femoral 
artery blood flow (ml/g/min); RFEM: resistance (mmHg/[ml/g/min]); (a-v)O2: oxygen extraction (ml/ml blood).  * p<0.05 versus 
LZR value.; † p<0.05 vs. strain control. 
 
 Figures 1 and 2 summarize data describing the pressor responses (Panels A), hindlimb 
blood flow (Panels B) and perfusion resistance (Panels C) in OZR versus LZR under control 
conditions and following treatment with phentolamine (Figure 1) and prazosin or yohimbine 
(Figure 2).  Any differences between LZR and OZR in terms of blood pressure and the 
pressor response to intravenous infusion of norepineprhine itself were abolished by 
treatment with either prazosin (the 1 blocker) or phentolamine (the 1/2 blocker), with 
minimal impact of yohimbine (the 2 blocker).    Treatment of OZR with TEMPOL (to blunt 
ROS and increase NO bioavailability) or TEMPOL/L-NAME (to remove NO bioavailability 
from a low ROS condition) had minimal impact on systemic responses to adrenergic 
challenges. 
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Figure 1.  In vivo pressor responses (Panel A), in situ hindlimb blood flow (Panel B) and calculated vascular resistance across 
the hindlimb (Panel C) for LZR and OZR following intravenous infusion of 10 mg/kg norepinephrine.  Data are presented as 
the change in the respective parameter from unstimulated, under control conditions and following pre-treatment with 
phentolamine (PHT), phentolamine+TEMPOL (PHT-TEM) or phentolamine+L-NAME (PHT-LNM). * p<0.05 vs. LZR in 
that condition; † p<0.05 vs. CON within that strain.  Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please 
see text for details. 
 72 
 
 
Figure 2.  In vivo pressor responses (Panel A), in situ hindlimb blood flow (Panel B) and calculated vascular resistance across 
the hindlimb (Panel C) for LZR and OZR following intravenous infusion of 10 mg/kg norepinephrine.  Data are presented as 
the change in the respective parameter from unstimulated, under control conditions and following pre-treatment with prazosin 
(PRZ), prazosin+TEMPOL (PRZ-TEM), prazosin+L-NAME (PRZ-LNM), yohimbine (YOH), yohimbine+TEMPOL (YOH-
TEM) or yohimbine+L-NAME (YOH-LNM).. * p<0.05 vs. LZR in that condition; † p<0.05 vs. CON within that strain. Data 
are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details. 
 Data describing the fatigue curves (Panel A), active hyperemia (Panel B), oxygen 
extraction (Panel C) and oxygen uptake (VO2; Panel D) for in situ gastrocnemius muscle of 
LZR and OZR contracting at 4Hz (isometric twitch) under control conditions and following 
treatment with phentolamine are presented in Figure 3.   Following three minutes of imposed 
elevations in metabolic demand, OZR demonstrated an increased development of muscle 
fatigue, co-incident with a blunted hyperemic response.  While O2 extraction was very similar 
between the two strains, the combination of extraction and reduced blood flow resulted in a 
significant reduction in VO2.  Treatment of OZR with the combined 1/2 adrenoreceptor 
antagonist phentolamine improved hyperemic responses when given alone, with additional 
improvements to muscle performance and VO2 when followed up with antioxidant 
(TEMPOL) treatment.  Treatment of OZR with prazosin (Figure 4) mirrored the effect of 
phentolamine, with an improved hyperemic responses when given alone and improved 
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muscle performance and VO2 when given with the antioxidant.  Any beneficial impacts of 
TEMPOL in OZR were abolished by combined treatment with TEMPOL and L-NAME.  
Treatment of OZR with the 2-adrenoreceptor antagonist yohimbine had no consistent or 
significant effect from control values on muscle performance, hyperemic responses or blood 
gas exchange measurements (Figure 5).   
 
 
Figure 3.  Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius 
muscle of LZR and OZR contracting at 4Hz (isometric twitch).  Also presented are O2 extraction (Panel C) and oxygen uptake 
(VO2, Panel D) at three minutes of the contraction regimen.  Data are presented under untreated control conditions and 
following pre-treatment with phentolamine (PHT), phentolamine+TEMPOL (PHT-TEM) or phentolamine+L-NAME (PHT-
LNM). * p<0.05 vs. LZR; † p<0.05 vs. OZR; ‡ p<0.05 vs. OZR + PHT.  Data are presented as mean±SE; n=5 for LZR; n=15 
for OZR; please see text for details. 
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Figure 4.  Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius 
muscle of LZR and OZR contracting at 4Hz (isometric twitch).  Also presented are O2 extraction (Panel C) and oxygen uptake 
(VO2, Panel D) at three minutes of the contraction regimen.  Data are presented under untreated control conditions and 
following pre-treatment with prazosin (PRZ), prazosin+TEMPOL (PRZ-TEM) or prazosin+L-NAME (PRZ-LNM). * p<0.05 
vs. LZR in that condition; † p<0.05 vs. CON (100%) within that strain; ‡ p<0.05 vs. PRZ within that strain.  Data are presented 
as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details. 
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Figure 5.  Data describing the performance (Panel A) and active hyperemic responses (Panel B) of in situ gastrocnemius 
muscle of LZR and OZR contracting at 4Hz (isometric twitch).  Also presented are O2 extraction (Panel C) and oxygen uptake 
(VO2, Panel D) at three minutes of the contraction regimen.  Data are presented under untreated control conditions and 
following pre-treatment with yohimbine (YOH), yohimbine+TEMPOL (YOH-TEM) or yohimbine+L-NAME (YOH-LNM). 
* p<0.05 vs. LZR in that condition.  Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details. 
 Table 3 presents the baseline characteristics of in situ cremaster muscle proximal and 
distal arterioles from LZR and OZR for the experiments described in Figures 6-9.   Figures 6 
and 7 summarize data describing the responses of in situ cremaster muscle arterioles located 
proximally within the microvascular network to bi-directional manipulation of adrenergic 
stimulation.  In response to increasing adrenergic stimulation (increased norepinephrine) 
proximal arterioles from both LZR and OZR exhibited robust constrictor responses (Figure 
6).  However, while arterioles from LZR exhibited a relatively consistent response, with 38/50 
vessels constricting by at least 60% of their resting diameter with 10-6 M norepinephrine, there 
was a significant shift in the distribution of reactivity with the development of the metabolic 
syndrome in OZR as only 19/50 vessels demonstrated a comparable  response, while 21/50 
vessels exhibited a stronger degree of reactivity, with a significantly reduced ED50 value, 
essentially closing off fully at lower concentrations of stimulation, and 10/50 vessels exhibited 
a significant reduction to constrictor responses, with an elevated ED50.  In both LZR and OZR, 
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treatment with either TEMPOL or L-NAME had minimal consistent impacts on adrenergic 
responses in either strain.  
Table 3.  Baseline vascular characteristics of 17 week-old LZR and OZR used in the present study under control 
conditions and in response to the different interventions.  Data are presented for in situ cremaster muscle proximal 
(CPA) and distal arterioles (CDA) as well as ex vivo gracilis muscle resistance arterioles (GA).  ID: internal diameter 
(resting; m); MaxD: maximum diameter (m) under 10-3M adenosine + 10-3M sodium nitroprusside (in situ) or Ca2+-
free conditions (ex vivo); AT: calculated active tone (%; please see text for detail).  Despite multiple trends, no 
significant differences in the results below were determined.   
 
 
 
 
Figure 6.  Constrictor responses from in situ cremaster muscle proximal arterioles from LZR (Panel A) and OZR (Panel D) 
in response to increasing concentrations of norepinephrine.  In Panels A and D, different levels of reactivity are colored such 
that “high” responders are red, “low” responders are green and “normal” responders are blue.  These colors are “greyed” in 
subsequent panels to facilitate comparisons.  Panels B and E present the impact of TEMPOL on arteriolar constrictor responses 
in LZR and OZR, respectively.   Panels C and F present the impact of L-NAME on arteriolar constrictor responses in LZR 
and OZR, respectively.   * p<0.05 vs. “normal” in that strain; † p<0.05 vs. responses in untreated arterioles within that strain 
and reactivity category.  Data are presented as mean±SE; n=7 for LZR; n=15 for OZR; please see text for details. 
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 With increasing phentolamine treatment (Figure 7), used to simulate progressive 
removal of adrenergic tone to proximal arterioles of LZR and OZR, “normal” responders in 
both strains exhibited comparable dilation.  However, arterioles in both strains that were 
identified as being “high” responders exhibited a very limited dilator response with increasing 
phentolamine concentration, while arterioles that were “low” responders to norepinephrine 
challenge demonstrated the greatest dilation in response to increasing concentration of 
phentolamine.  In both strains, neither TEMPOL nor L-NAME treatment had a consistent and 
significant impact on the phentolamine-induced dilation in “normal” and “high” responders. 
However, in “low” responders of either strain, treatment of arterioles with L-NAME blunted 
dilator responses to phentolamine.  
 
Figure 7.  Dilator responses from in situ cremaster muscle proximal arterioles from LZR (Panel A) and OZR (Panel D) in 
response to increasing concentrations of phentolamine.  In Panels A and D, different levels of reactivity are colored such that 
“high” responders are red, “low” responders are green and “normal” responders are blue (classification of responders was 
performed for Figure 8).  These colors are “greyed” in subsequent panels to facilitate comparisons.  Panels B and E present 
the impact of TEMPOL on arteriolar dilator responses in LZR and OZR, respectively.   Panels C and F present the impact of 
L-NAME on arteriolar dilator responses in LZR and OZR, respectively.   * p<0.05 vs. “normal” in that strain; † p<0.05 vs. 
responses in untreated arterioles within that strain and reactivity category.  Data are presented as mean±SE; n=7 for LZR; 
n=15 for OZR; please see text for details. 
 Using the data presented above, Figure 8 presents the relationship between in situ 
proximal arteriolar constrictor responses to 10-8 M norepinephrine and the number of 
occurrences (out of a total n=50 for each strain).  These data clearly illustrate the changing 
distribution in constrictor responses to adrenergic challenge, where LZR exhibit a tighter 
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distribution of responses with lower variability than OZR, where proximal arteriolar responses 
to adrenergic challenge are more distributed, with a greater occurrence of constrictor 
responses at the “tails” of the distribution.  Statistical analysis of the mean and variance 
between LZR and OZR demonstrated that the distributions of adrenergic responses where 
significantly different between the two strains. 
 
Figure 8.  Distribution of constrictor responses of in situ cremaster muscle proximal arterioles to 10-8 M norepinephrine.  Data 
are presented as the frequency of occurrence for a level of constrictor response (out of 50 occurrences) for arterioles from LZR 
and OZR; demonstrating the widening and flattening of the distribution in OZR as compared to that for LZR.  The distribution 
for LZR passes the normality test (p=0.834), while that for OZR does not (p=0.025).  As such, while the distributions for LZR 
and OZR are considered to be significantly different (p=0.026), they cannot both be classified as normal distributions. 
 Figure 9 presents the responses of distal in situ cremaster muscle arterioles of LZR 
and OZR to increasing concentrations of norepinephrine (Panels A and B) and phentolamine 
(Panels C and D), respectively.  Under neither control conditions, nor pre-treatment conditions 
(TEMPOL or L-NAME) were responses of in situ distal arterioles significantly different 
between strains, nor was any evidence for an altered distribution of reactivity present (Panel 
E). 
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Figure 9.  Mechanical responses from in situ cremaster muscle distal arterioles from LZR (Panel A) and OZR (Panel B) in 
response to increasing concentrations of norepinephrine (Panels A and B, respectively) or phentolamine (Panels C and D, 
respectively).  Data are presented under untreated control conditions and following pre-treatment of the cremaster muscle with 
TEMPOL or L-NAME.  Also presented is the distribution of constrictor responses of in situ cremaster muscle proximal 
arterioles to 10-8 M norepinephrine (Panel E).  Data are presented as the frequency of occurrence for a level of constrictor 
response (out of 50 occurrences) for arterioles from LZR and OZR; demonstrating the lack of a difference between the 
distribution for LZR and OZR (p=0.909).  Data are presented as mean±SE; n=7 for LZR; n=15 for OZR; please see text for 
details.  Please see text for details. 
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 Figure 10 presents the reactivity of ex vivo gracilis muscle first order resistance 
arterioles of LZR and OZR to increasing concentrations of the 1 adrenoreceptor agonist 
phenylephrine (for data describing the baseline characteristics of ex vivo arterioles, please see 
Table 3).  When the inclusion criteria of “sufficient adrenergic reactivity” was eliminated 
(please see above), a similar widening of constrictor responses to adrenergic challenge was 
determined in OZR as compared to LZR (Panel A).  In “high” responders, the increased 
constrictor reactivity was significantly attenuated following treatment of the vessel with 
TEMPOL, while treatment with L-NAME was without effect (Panel B).  This effect was less 
evident in “normal” (Panel C) and “low” (Panel D) responding arterioles from OZR, such that 
treatment with either TEMPOL or L-NAME resulted in minimal impact to phenylephrine-
induced reactivity. Constrictor responses to increasing concentrations of the 2 
adrenoreceptor agonist clonidine did not exhibit a difference between LZR and OZR (Panel 
E), and this was not significantly impacted by treatment with TEMPOL or L-NAME. 
 81 
 
 
Figure 10.  Constrictor responses from ex vivo gracilis muscle resistance arterioles from LZR and OZR in response to 
increasing concentrations of phenylephrine (α1 agonist; Panels A-D) or clonidine (α2 agonist; Panel E).  Data for 
phenylephrine-induced constriction under control conditions are presented in Panel A, which also demonstrate the different 
classes of reactivity.  These data are “greyed” in subsequent panels such that the impact of pre-treatment with TEMPOL, L-
NAME or both are presented for vessels in the “high” (Panel B), “normal” (Panel C) and “low” responder (Panel D) categories.  
* p<0.05 vs. “normal” in that strain; † p<0.05 vs. responses in untreated arterioles within that strain and reactivity category.  
Data are presented as mean±SE; n=5 for LZR; n=15 for OZR; please see text for details. 
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3.5 Discussion 
 The underlying logic of the present study stemmed from a lack of clarity between the 
results of previous studies suggesting an increase in sympathetic activity (5), adrenergic 
constrictor reactivity (9, 11) and an increase in some elements of adrenergic intracellular 
signaling (21) in metabolic syndrome, despite the consistent observation that the development 
of both hypertension and any elevations in vascular resistance of adrenergic origin were 
relatively modest (4, 12, 16, 29).  This suggests that a potential disconnect may exist between 
the interpretations from data collected at higher resolutions (e.g., in situ vascular networks, ex 
vivo resistance vessels), and responses determined under in vivo conditions.  The present study 
was designed to address this discrepancy by identifying the source for this lack of clarity. 
 At the lowest level of spatial resolution, the in vivo preparation, OZR clearly exhibited 
an increased pressor response following adrenergic challenge as compared to responses 
determined in LZR, while use of adrenoreceptor antagonists demonstrated that this increased 
response was largely mediated via the 1 receptors.   While consistent with previous evidence 
(9, 11), results from the present study also provide insight into the role of vascular oxidant 
stress/nitric oxide bioavailability balance on the pressor response to adrenoreceptor 
stimulation.  Despite the clearly established presence of elevated vascular oxidant stress in 
OZR, the current results suggest that the reduction in vascular ROS levels following 
TEMPOL treatment was without significant impact on the magnitude of the pressor response 
in OZR, nor did the subsequent L-NAME–based abolition of rescued nitric oxide 
bioavailability consistently impact the magnitude of the pressor responses between groups.  
Given the well-established relationships in question and the effectiveness of the treatment 
interventions in impacting ROS and NO levels, the most reasonable interpretation of these 
data is that, in comparison to the 1-mediated responses, a manipulation of vascular nitric 
oxide bioavailability was of insufficient significance to impact pressor responses at this level 
of resolution. 
 When taking these observations to the next higher level of resolution, the in situ 
skeletal muscle, a roughly comparable condition was evident to that for the in vivo setting.  
Specifically, the accelerated rate of muscle fatigue and blunted active hyperemia with 4Hz 
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twitch contraction in OZR vs. LZR were improved following 1 receptor blockade (but only 
with concurrent antioxidant treatment); with no significant effect associated with 2 receptor 
antagonism under any condition. This enhanced function was associated with the greatest 
improvements to VO2 which also suggests that the combination of adrenoreceptor antagonism 
and antioxidant therapy results in an overall improvement to the perfusion-based elements of 
mass transport and exchange beyond that for 1 adrenoreceptor antagonism alone.  Further, 
the importance of “rescued” vascular nitric oxide bioavailability on contributing to skeletal 
muscle blood flow, especially during periods of elevated metabolic demand, was 
demonstrated following the application of L-NAME under TEMPOL-treated conditions.   
 These results also provide support for previous observations indicating that general 
blunting of adrenergic constriction can improve hyperemic responses in skeletal muscle in 
metabolic syndrome (8, 9, 11, 21), but are of limited effectiveness in terms of improving 
muscle performance unless treatments are combined with antioxidant agents to directly 
improve endothelial function (8).  As antioxidant treatment alone was without impact on either 
bulk flow responses or muscle performance in the absence of 1 adrenoreceptor inhibition, 
these observations suggest that a conceptual division may be appropriate for the impact of the 
metabolic syndrome muscle performance outcomes.  It may be that the modest reduction in 
skeletal muscle blood flow in OZR primarily reflects adrenergic constraint sufficient to hinder 
metabolic sympatholysis, while endothelial dysfunction (although ubiquitously present) is 
more important for the higher resolution matching of perfusion distribution to metabolic need 
within tissue.   
 Previous studies have suggested that there is a general increase in sympathetic traffic, 
intracellular signaling, and/or vascular constrictor responses to adrenergic challenge with the 
development of metabolic syndrome (5, 9, 21).  However, as stated above, in vivo data do not 
strongly support this contention.  Results from the in situ cremaster muscle of OZR as 
compared to responses in LZR may provide insight into this discrepancy, as constrictor 
responses of proximal resistance arterioles to increasing adrenergic stimulation exhibited a 
much more consistent response in LZR than in OZR, with a narrower distribution.  In contrast, 
the responses to adrenergic challenge in OZR exhibited a larger spread in their magnitude 
with a greater proportion of vessels demonstrating both increased and decreased 
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responsiveness (although more commonly toward increased reactivity).  Similarly, when 
treated with increasing concentrations of the 1/2 adreneroreceptor antagonist phentolamine, 
arterioles that were classified as “high responders” exhibited the lowest degree of dilation, 
while the reverse was true for vessels that were “low responders”.   Obviously, this somewhat 
skewed, but broader distribution of adrenergic constrictor responses, may contribute to the in 
vivo outcomes that have been identified in OZR, and may explain why they are more modest 
than would otherwise be predicted.  
 Based on the current data, some of this heterogeneity in reactivity may reflect 
variability in the initial conditions.  Arterioles with increased tone under resting conditions 
will be unable to exhibit the full range of constriction in response to any stimulus as compared 
to levels from those of a greater initial diameter/reduced level of tone.  Conversely, those with 
less tone (greater diameter) at rest have less ability to respond to the removal of adrenergic 
constriction as compared to those with a greater degree of tone.  Given this, the greater 
heterogeneity of reactivity in the microcirculation of OZR vs. LZR may reflect the concept of 
the “optimal diameter” or “optimal wall tension” as originally described by Gore (14).  In that 
work, the author determined that the greatest degree of reactivity was realized when vessels 
had the ability to constrict or dilate through a set range of optimal responsiveness and that 
moving the initial condition away from this range in either direction was associated with a 
severe decline in stimulus-induced reactivity.  It may be that the more heterogeneous 
reactivity of proximal resistance arterioles from OZR in response to adrenergic challenge 
could partially reflect a loss of coordination through the sympathetic nerves that results in an 
increasingly heterogeneous initial “resting” condition which impacts adrenergic control over 
resistance at both the individual vessel and network levels.   Recent work by Rachev and 
colleagues (22) has shed further light on this concept and provided compelling evidence of an 
optimal state of vascular mechanics that may result in the most efficient adaptability to 
changing conditions. 
 Interestingly, the increased variability in resistance arteriolar adrenergic reactivity in 
OZR following development of the metabolic syndrome in proximal arterioles, was not 
evident in distal arterioles. Using intravital microscopy, our group has shown that adrenergic 
vasoconstriction, in the rat gluteus maximus microcirculation, displays spatial-dependency. 
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In this work, we reported that the greatest 1R and 2R effects were noted in lower order 
(proximal) arterioles (i.e., 1A and 2A); whereas, sympathetically-mediated peptidergic and 
purinergic control dominated in higher order distal and terminal arterioles (2). Such spatial 
heterogeneity in sympathetic control provides a plausible explanation for the lack of 
adrenergic influences measured in distal microcirculation of OZR. Thus, future work 
addressing the contributions of NPY and ATP to microvascular regulation/dysregulation in 
the metabolic syndrome will likely reveal new mechanisms of sympathetic dysregulation in 
the distal microcirculation.  
 An important component of the present study was the removal of “robust adrenergic 
reactivity” as an inclusion criterion for the study of ex vivo resistance arterioles.  When this 
was incorporated, a comparable pattern of divergence in adrenergic constrictor reactivity is 
present in the larger resistance arterioles of OZR vs. LZR to that for the proximal arterioles 
within the cremaster muscle.    The increased variability in the adrenergic constrictor reactivity 
of ex vivo arterioles of OZR appears to reflect intrinsic vascular, and perhaps endothelial cell, 
function itself, as treatment of “high responders” with TEMPOL blunted the adrenergic 
responses, which was subsequently abolished following additional treatment with L-NAME.  
These effects were not observed in “normal” or “low” responders where the ability of 
TEMPOL and/or L-NAME to impact adrenergic constriction was severely attenuated.  As a 
result of a relaxed inclusion criteria, the magnitude of the net increase in adrenergic 
constriction in large resistance arterioles of OZR was elevated as compared to LZR, but to a 
far less extent than previously estimated.   
 The results of the present study are important for several reasons.  Foremost, these 
data provide evidence for the role of altered adrenoreceptor reactivity in the metabolic 
syndrome on integrated vascular function from a multi-scale perspective.  Clearly, the 
increased pressor response to adrenergic challenge largely reflects activity mediated through 
the 1 receptor and does not appear to be substantially impacted by treatment against elevated 
oxidant stress or a potential loss in vascular nitric oxide bioavailability.  While responses from 
the hindlimb preparation suggested that hyperemic responses of OZR skeletal muscle can be 
improved by 1 adrenoreceptor inhibition, additional antioxidant treatment of OZR was 
required to improve muscle performance, suggesting divergent roles for adrenergic constraint 
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on bulk flow and endothelial function for higher resolution perfusion:demand matching.  
Finally, results at the highest levels of spatial resolution, the in situ cremaster muscle and ex 
vivo microvessel revealed an increased diversity of vascular reactivity in OZR following 
adrenergic challenge.  The immediate question from these results is why an increased diversity 
of adrenergic constrictor reactivity develops in OZR with progression of metabolic syndrome.     
 There does not appear to be evidence that a compensatory change in constrictor 
reactivity for the shifts in adrenergic responses develops in OZR, as there is no evidence that 
changes in myogenic activation between strains or within an individual animal that would 
match with increased adrenergic reactivity heterogeneity exists (i.e., vessels with low 
adrenergic reactivity having elevated myogenic responses, etc.).  Additionally, there is no 
prior evidence to which the authors are aware that constrictor responses to other agents (e.g., 
endothelin, angiotensin II, serotonin) are significantly altered in OZR (27).  However, there 
is evidence from some investigators that pressor reflexes may be blunted in OZR, although 
the mechanism underlying this and its generalizability for the model remain unclear (25).  As 
such, one is left with speculation.  Do vessels with “low” adrenergic constriction help the 
networks maintain an appropriate active hyperemic response, or at least largely maintain it?  
In an animal model that has been established as suffering from a profound loss of the 
microvascular network flexibility necessary to respond to imposed stressors (8), does the 
increased heterogeneity of adrenergic responses help to maintain system flexibility?    
 Perhaps even more importantly for clinical/population health outcomes, alterations in 
adrenergic tone and function have been previously implicated as contributing to the regulation 
of microvessel density, and chronic 1 adrenoreceptor inhibition with prazosin is an 
established systemic model of angiogenesis (30).  Of greatest relevance to the present study, 
may be recent work from the Haas group, where chronic prazosin treatment blunted the 
development of microvessel rarefaction in chronic corticosterone-treated rats (20).  Given the 
presence of high cortisol/corticosterone levels in OZR, it may be that tissue regions containing 
resistance arterioles with elevated adrenergic reactivity may be associated with earlier or more 
severe levels of microvascular rarefaction (12).  At this point, answers to the above questions 
are unknown.  However, the challenge that the metabolic syndrome and PVD risk pose for 
public health outcomes (26), combined with the clear potential for improving microvascular 
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network function and perfusion with appropriate intervention, make this a compelling avenue 
for future investigation. 
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4.1 Abstract 
It has been long known that chronic metabolic disease is associated with a parallel increase 
in the risk for developing peripheral vascular disease.  Although more clinically relevant, 
our understanding about reversing established vasculopathy is limited in comparison to our 
understanding of the mechanisms and development of impaired vascular structure/function 
under these conditions.  Using the 13-week old obese Zucker rat (OZR) model of the 
metabolic syndrome, where microvascular dysfunction is sufficiently established to 
contribute to impaired skeletal muscle function, we imposed a 7-week intervention of 
chronic atorvastatin (ATOR) treatment, chronic treadmill exercise (EXER), or both.  By 
20 weeks of age, untreated OZR manifested a diverse vasculopathy that was a central 
contributor to poor muscle performance, perfusion and impaired O2 exchange.  ATOR or 
EXER, with the combination being most effective, improved skeletal muscle vascular 
metabolite profiles (i.e., nitric oxide, PGI2 and TxA2 bioavailability), reactivity and 
perfusion distribution at both individual bifurcations and within the entire microvascular 
network versus responses in untreated OZR. However, improvements to microvascular 
structure (i.e., wall mechanics and microvascular density) were less robust.  The 
combination of the above improvements to vascular function with interventions resulted in 
an improved muscle performance and O2 transport and exchange versus untreated OZR, 
especially at moderate metabolic rates (3Hz twitch contraction).  These results suggest that 
specific interventions can improve specific indices of function from established 
vasculopathy, but this process was either incomplete after 7 weeks duration or that 
measures of vascular structure are either resistant to reversal or require better targeted 
interventions. 
 
Key Words:  vascular dysfunction, rodent models of the metabolic syndrome, regulation of 
blood flow, peripheral vascular disease, microvascular dysfunction, reversing vascular 
disease 
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New and Noteworthy 
We used atorvastatin and/or chronic exercise to reverse established microvasculopathy in 
skeletal muscle of rats with metabolic syndrome.  With established vasculopathy, 
atorvastatin or exercise had moderate abilities to reverse dysfunction, combined 
application of both was more effective at restoring function.  However, increased vascular 
wall stiffness and reduced microvessel density were more resistant to reversal.   
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4.2 Introduction 
One of the major contributors to the functional or clinical manifestations of 
peripheral vascular disease is the progressive loss of microvessel and microvascular 
network structure and function which is tightly coupled to developing metabolic disease in 
afflicted animals (9, 15) or humans (20, 25).  This compromised function within the 
microcirculation can take multiple forms, including impairments to arteriolar reactivity, 
mechanical changes to the microvessel wall, and a progressive lowering of microvessel 
density (rarefaction) within the skeletal muscle (14, 26).  Taken together, these impede 
effective mass transport and exchange, and the regulation of blood flow to, and perfusion 
within, skeletal muscle (9, 23).  In addition, while the functional impact of these 
impairments may be modest under resting or low-metabolic demand conditions, their 
cumulative impact becomes more severe as muscle activity increases (6, 13, 28).  Given 
the insidious nature of the development of peripheral vascular diseases (PVD), and the very 
real clinical challenge of reversing the development of established vasculopathy in affected 
patients (rather than blunting its subsequent development from an otherwise “healthy” 
condition), investigation into if/how a compromised microvascular network can be restored 
to a more normal level of structure and integrated function represents an important area of 
investigation.  Arterial reconstructive surgery for symptomatic PVD can restore 
macrovascular perfusion but its effects on microvascular dysfunction are unclear. 
Persistent microvascular dysfunction following successful macrovascular reperfusion may 
explain why arterial reconstruction does not always lead to wound healing or amelioration 
of symptoms in patients with PVD (12) 
Previous studies in our laboratory (13, 14) and from others (9, 31-34) have clearly 
established that the loss of normal microvascular structure and function parallels the 
development of metabolic disease.  Of particular relevance to the present study, we have 
recently demonstrated that rarefaction in the skeletal muscle of the obese Zucker rat (OZR) 
appears to develop in stages, where an early reduction of microvessel density is well 
predicted by an oxidant stress- and inflammation-dependent shift in arachidonic acid 
metabolism toward increasing levels of thromboxane A2 (TxA2), with a later stage of 
rarefaction that is associated with a loss in vascular nitric oxide bioavailability (14).   
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However, any interventions that have been employed to improve these vascular outcomes 
have been relevant for blunting the severity of the vasculopathy that ultimately develops, 
rather than reversing an established compromised condition once it has already developed 
(16, 18).  
The OZR (fa/fa) represents a model of the metabolic syndrome that is 
fundamentally grounded in a mutation in the leptin receptor leading to severe leptin 
resistance, chronic hyperphagia and the ensuing development of severe obesity (2, 11).  
Tracking with the severe obesity is a steadily worsening glycemic control, a progressive 
dyslipidemia and a moderate hypertension, with the additional co-morbidities of a growing 
pro-oxidant, pro-inflammation, and pro-thrombotic state (22).  OZR exhibit high 
translational relevance to the metabolic syndrome condition in humans (29) and manifest 
a progressively worsening skeletal muscle microvascular structure and function that 
parallels that determined in affected humans.   
The purpose of the present study was to utilize two clinically-relevant interventions 
against the further development of established PVD – increased physical activity/exercise 
and chronic ingestion of the HMG CoA-reductase inhibitor atorvastatin – to determine if 
an established impairment to skeletal muscle arteriolar and microvascular structure and 
function can be reversed toward normal prior to reaching its maximum severity.  For this 
study, “reversibility” is defined as the effectiveness of the imposed intervention in OZR to 
restore the normal level of measured parameter (e.g., nitric oxide bioavailability) to that 
determined in untreated LZR.  This study tested the hypothesis that, once developed, 
skeletal muscle microvascular impairments in the OZR model of the metabolic syndrome 
cannot be reversed, as the environment within the microvasculature cannot be modified 
sufficiently to generate a condition that allows for reversibility.  We propose that a deeper 
understanding of the reversibility of skeletal muscle microvasculopathy that occurs in 
metabolic disease will provide greater insight into the clinical challenge of most direct 
relevance to human subjects. 
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4.3 Materials and Methods 
Animals:  Male lean (LZR) and OZR (Harlan) were fed standard chow and drinking water ad 
libitum, unless otherwise indicated, were housed in an accredited animal care facility at either 
the West Virginia University Health Sciences Center (all experimental procedures) or at the 
University of Western Ontario (ex vivo vascular experiments only) and all protocols received 
prior IACUC approval.   Animals were used for terminal experiments at 13 (initial condition) 
or 20 (following intervention) weeks of age.  At 13 weeks of age, LZR and OZR (n=6 for 
each) were either used for terminal experiments (to establish the initial condition within the 
microcirculation) or were placed into one of four groups: 
1. Time control (n=6; rats were housed without intervention and aged to ~20 weeks) 
2. Atorvastatin (n=6; 25 mg•kg-1•day-1; mixed with food; Ref.18) 
3. Treadmill exercise (n=6; 20 m/min, 5% incline, 60 minutes/day, 6 days/week; Ref. 
16) 
4. A combination of atorvastatin treatment and treadmill exercise as described above, to 
~20 weeks of age; n=6. 
At the time of final usage, after an overnight fast, rats were anesthetized with injections of 
sodium pentobarbital (50 mg/kg, i.p.), and received tracheal intubation to facilitate 
maintenance of a patent airway.  In all rats, a carotid artery and an external jugular vein were 
cannulated for determination of arterial pressure and for infusion of supplemental anesthetic 
or pharmacological agents, as necessary.  Blood samples were drawn from the venous cannula 
within approximately 20 minutes following implantation for determination of insulin 
concentrations (Cayman Chemical Company, Ann Arbor, MI), plasma nitrotyrosine levels 
and markers of inflammation using commercially available EIA systems (Luminex 100 PS; 
EMD Millipore, Billerica, MA).  While glucose levels were determined at the time of the 
blood draw (Freestyle, Abbott Diabetes Care, Inc, Alameda, CA), all other samples were spun 
to remove the plasma, which was snap frozen in liquid N2 until they could be analyzed as 
groups.     
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized rats, prior 
to the preparation of the cremaster muscle (below), the intramuscular continuation of the 
right gracilis artery was identified, the in vivo length and diameter estimated using an 
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eyepiece micrometer, and the vessel was surgically removed and doubly-cannulated (7).  
Within each arteriole, vessel reactivity was evaluated in response to application of 
acetylcholine (10-9 M – 10-6 M) or hypoxia (reduction in PO2 from ~135 mmHg to ~50 
mmHg).  Subsequently, vessels were treated with TEMPOL (10-4 M) to assess the 
contribution of vascular oxidant stress to these mechanical responses.   
At the conclusion of all procedures described above, vessel diameter was 
determined under Ca2+-free conditions over a range of intraluminal pressures spanning 0 
mmHg to 160 mmHg (in 20 mmHg increments) for the subsequent calculation of wall 
mechanics.  For these procedures, 5 mmHg was used as the “zero pressure” condition to 
prevent vessel collapse and to eliminate the potential for creating a vacuum within the 
vessel. 
Preparation of In Situ Cremaster Muscle: In each rat, the left cremaster muscle was 
prepared for television microscopy (24).  After completion of the preparation, the muscle was 
superfused with PSS, equilibrated with a gas mixture containing 5% CO2 and 95% N2, and 
maintained at 35C as it flowed over the muscle at a rate of 2.5 – 3.0 ml/min.  The ionic 
composition of the PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl2 1.6, NaH2PO4 
1.18, MgSO4 1.17, NaHCO3 24.0, and disodium EDTA 0.03. After an initial post-surgical 
equilibration period of 30 minutes, two sets of arterioles and their bifurcations were selected.  
Proximal (~75 m diameter) and distal (~40 m) parent arterioles and their immediate 
daughter branches were selected for investigation in a clearly visible region of the muscle 
(please see reference 17 for a full description).  All arterioles chosen for study had walls that 
were clearly visible, a brisk flow velocity, and active tone, as indicated by the occurrence of 
significant dilation in response to topical application of 10-5 M adenosine.  All arterioles that 
were studied were located in a region of the muscle that was away from any incision.   
Initial evaluations of in situ arteriolar reactivity were assessed by determining mechanical 
responses (using on-screen videomicroscopy) to increasing concentrations of acetylcholine 
(10-9-10-6 M) and norepinephrine (10-10-10-7 M).  Subsequently, the diameter and perfusion 
(using optical Doppler velocimetry) responses of both the ‘parent’ and ‘daughter’ arterioles 
at either level of the microcirculation were assessed under resting conditions within the 
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cremaster muscle of each rat.  All procedures were then repeated following treatment of 
the in situ cremaster muscle with the anti-oxidant TEMPOL (10-3 M; within the 
superfusate; for a minimum of 40 minutes prior to any subsequent data collection).   
Measurement of Vascular NO Bioavailability: From each rat, the abdominal aorta was 
removed and vascular NO production was assessed using amperometric sensors (World 
Precision Instruments, Sarasota, FL).  Briefly, aortae were isolated, sectioned 
longitudinally, pinned in a silastic coated dish and superfused with warmed (37C) PSS 
equilibrated with 95% O2 and 5% CO2.  An NO sensor (ISO-NOPF 100) was placed in 
close apposition to the endothelial surface and a baseline level of current was obtained.  
Subsequently, increasing concentrations of methacholine (10-10–10-6 M) were added to the 
bath and the changes in current were determined.  To verify that responses represented NO 
release, these procedures were repeated following pre-treatment of the aortic strip with L-
NAME (10-4 M).   
Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-
keto-prostaglandin F1 (6-keto-PGF1; the stable breakdown product of PGI2; Ref. 27), and 
11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product of 
TxA2; Ref. 8) was assessed in response to challenge with reduced PO2 using pooled arteries 
(femoral, saphenous, iliac) from LZR and OZR.  Pooled arteries from each animal were 
incubated in microcentrifuge tubes in 1 ml of PSS for 30 minutes under control conditions 
(21% O2).  After this time, the superfusate was removed, stored in a new microcentrifuge tube 
and frozen in liquid N2, while a new aliquot of PSS was added to the vessels and the 
equilibration gas was switched to 0% O2 for the subsequent 30 minutes.  After the second 30-
minute period, this new PSS was transferred to a fresh tube, frozen in liquid N2 and stored at 
-80C.  Metabolite release by the vessels was determined using commercially available EIA 
kits for 6-keto-PGF1 and 11-dehydro-TxB2 (Cayman). 
Histological Determination of Microvessel Density:  From each rat, the gastrocnemius 
muscle from the left leg was removed, rinsed in PSS and fixed in 0.25% formalin.  Muscles 
were embedded in paraffin and cut into 5 m cross sections.  Sections were incubated with 
Griffonia simplicifolia I lectin (GS-1) for subsequent determination of microvessel density.  
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GS-1 is a general stain that labels all microvessels <20 m in diameter (19).  Gastrocnemius 
muscle microvessel density was determined using fluorescence microscopy) as described 
previously (14). 
Preparation of In Situ Blood Perfused Gastrocnemius: In a separate set of age-matched 
LZR and OZR under the conditions outlined above, the left gastrocnemius of each animal 
was isolated in situ (13).  Heparin (500 IU/kg) was infused via the jugular vein to prevent 
blood coagulation.  Subsequently, an angiocatheter was inserted into the femoral artery, 
proximal to the origin of the gastrocnemius muscle to allow for bolus tracer injection.  
Additionally, a small shunt was placed in the femoral vein draining the gastrocnemius muscle 
that allowed for diversion of flow into a port which facilitated sampling of the venous effluent.  
Finally, a microcirculation flow probe (Transonic; 0.5/0.7 PS) was placed on the femoral 
artery to monitor muscle perfusion.   
Following completion of the surgical preparation and 30 minutes of self-perfused rest, 
the muscle was stimulated via the sciatic nerve to contract for 3 minutes at either 3 or 5 Hz 
isometric twitch contractions, separated by 15 minutes of self-perfused rest.  Muscle tension 
development and blood flow were monitored continuously, and arterial and venous blood 
aliquots were taken within the final 30 seconds for the determination of blood gas content. 
Upon completion of the contraction protocols, the gastrocnemius muscle was allowed 
at least 20 minutes of rest for full recovery.  At this point, 20 l of 125I-albumin (10 Ci; 
Perkin-Elmer, Shelton, CT) was injected as a spike bolus (injection time <0.5 s) into the 
arterial angiocatheter and venous effluent samples were collected at a rate of 1/s for the 
subsequent 35 seconds. Venous effluent samples were then immediately transferred into 
silicate tubes and placed into a gamma counter for activity determination.  In order to assess 
the potential for leakage of the labeled albumin from the intravascular space as a source 
for error, the gastrocnemius muscle was cleared by perfusion with PSS following 
euthanasia.  Subsequent to a determination of mass, the muscle was placed in the counter 
for determination of residual activity.  Residual activity within the gastrocnemius muscle 
did not exceed 200 cpm/animal, a level that was far lower than those determined in the 
venous blood aliquots.     
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Mathematical Analyses of Results:  Arteriolar perfusion in both parent and daughter vessels 
within in situ cremaster muscle of LZR and OZR was calculated as:  
)001.0)()(6.1( 21 rVQ −=     Equation 1 
where Q represents arteriolar perfusion (nl•s-1), V represents the measured red cell 
velocity from the optical Doppler velocimeter (mm•s-1; with V/1.6 representing an 
estimated average velocity assuming a parabolic flow profile; Ref. 10), and r represents 
arteriolar radius (m; Ref. 3).    
The total volume perfusion in the daughter arterioles was determined as the sum of 
the individual perfusion rates, and the proportion of flow within each was determined as the 
quotient of the individual branch divided by the total.   is defined as the ratio of the greater 
of the two flows in the daughter vessel to the total flow in the parent vessel.  As an example, 
if flow distribution was homogeneous between daughters,  for that bifurcation would be 0.5 
in both daughter arterioles, while if the proportion of flow in one daughter arteriole was 60%, 
 for that bifurcation would be 0.6, with flow distribution being 0.6 in the ‘high perfusion’ 
arteriole and 0.4 in the ‘low perfusion’ arteriole (13).  For the present study, following the 
initial determination of  (described above) we determined the changes in  every 20 seconds 
over the subsequent 5-minute period.   
The dilator or constrictor responses of ex vivo microvessels or aortic rings following 
agonist challenge were fit with the three-parameter logistic equation: 




+
−
+=
−xED
y
50log101
minmax
min      Equation 2 
where y  represents the change in arteriolar diameter, “min” and “max” represent the 
lower and upper bounds, respectively, of the change in diameter or tension with increasing 
agonist concentration, x  is the logarithm of the agonist concentration, and 50log ED  
represents the logarithm of the agonist concentration ( x ) at which the response ( y ) is 
halfway between the lower and upper bounds.     
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Vascular NO bioavailability measurements were fit with a linear regression equation: 
xy 10  +=       Equation 3 
where y  represents the NO concentration, ∝0 represents an intercept term, 𝛽1 
represents the slope of the relationship, and 𝑥 represents the log molar concentration of 
methacholine.  
The determination of passive arteriolar wall mechanics (used as indicators of 
structural alterations to the individual microvessel) are based on those used previously (5), 
with minor modification.  For the calculation of circumferential stress, intraluminal 
pressure was converted from mmHg to N/m2, where 1 mmHg=1.334102 N/m2.   
Circumferential stress () was then calculated as: 
     Equation 4 
where ID represents arteriolar inner diameter (m), and WT represents wall thickness (m) 
at that intraluminal pressure (PIL).  Circumferential strain () was calculated as: 
     Equation 5 
where ID5 represents the internal arteriolar diameter at the lowest intraluminal pressure 
(i.e., 5 mmHg). 
The stress versus strain relationship from each vessel was fit (ordinary least squares 
analyses, r2>0.85) with the following exponential equation: 
      Equation 6 
where 5 represents circumferential stress at ID5 and  is the slope coefficient describing 
arterial stiffness. Higher levels of  are indicative of increasing arterial stiffness (i.e., 
requiring a greater degree of distending pressure to achieve a given level of wall 
( )
( )WT
IDPIL
2

=
( )
5
5
ID
IDID −
=
 e5=
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deformation). 
In specific experiments, 200 l blood samples were drawn from the carotid artery 
cannula and femoral vein angiocatheter immediately prior to and following completion of, the 
muscle contraction periods.  Samples were stored on ice until they were processed for blood 
gas pressures, percent oxygen saturation and hemoglobin concentration using a Corning 
Rapidlab 248 blood gas analyzer.  Muscle perfusion, arterial pressure, and bulk blood flow 
through the femoral artery were monitored for one minute prior to muscle contractions and 
throughout the contraction period using a Biopac MP150 with Acqknowledge data acquisition 
software at a 50Hz sampling frequency.  Muscle perfusion and performance data after three 
minutes of contraction were normalized to gastrocnemius mass, which was not different 
between LZR (2.180.09 g) and OZR (2.060.10 g).  Oxygen content within the blood 
samples was determined using the following standard equation:  
  )003.0()%][39.1( 222 OPSatOHbOC xx +=   Equation 7 
Where CxO2 and PxO2 represent the total content (ml/dL) or partial pressure of oxygen 
(mmHg), respectively, of arterial or venous blood (denoted simply as ‘x’). [Hb] represents 
hemoglobin concentration within the blood sample (g/dL); %O2Sat represents the percentage 
oxygen saturation of the hemoglobin and 1.39 and 0.003 represent constants describing the 
amounts of bound and dissolved oxygen in blood.  Oxygen uptake across the gastrocnemius 
muscle was calculated using the Fick equation:  
  ( )222 CvOCaOQVO −=      Equation 8 
where VO2 represents oxygen uptake by the gastrocnemius muscle, Q represents femoral 
artery blood flow (ml/g/min), and CaO2 and CvO2 represent arterial and venous oxygen 
content, respectively. 
Analyses of Tracer Washout Curves:  For the 125I-albumin washout, four standard 
parameters describing characteristics of tracer washout curves, including mean transit time 
( t ), relative dispersion (RD), skewness ( 1 ), and kurtosis ( 2 ), were computed as 
functions of the transport function h(t) (4). As described in our recent study (17), the tails 
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of the tracer washout curves were extrapolated in the form of single exponential time course 
to allow for computing the four parameters by the integration for sufficiently long time for 
convergence (21). In this study, experimentally-measured time courses are extrapolated to 
100 seconds, at which C(t) is estimated to be less than 10-9 of the maximum washout tracer 
activity.  The transport function h(t) is estimated from 
0
h( ) C( ) C( )t t t dt

=        Equation 9 
where C(t) is the time course of activity of intravascular tracer in outlet flow exiting the 
collecting tube.  The mean transit time t  is calculated from experimentally measured 
washout curves according to: 
0
h( )t t t dt

=        Equation 10 
The RD of h(t) is a measure of the relative temporal spread of h(t) and computed as the 
ratio of standard deviation of h(t) to the mean transit time from: 
( )
1/ 2
2
0
h( )d /RD t t t t t
 
= −  
 
     Equation 11 
The skewness ( 1 ) is a measure of asymmetry of h(t) and computed from: 
( ) ( )
3/ 2
3 2
1
0 0
h( )d h( )dt t t t t t t t
  
= −  −  
 
                   Equation 12  
Skewness is a measure of the asymmetry of the perfusion distribution.  In other words, it 
is a measure of the extent to which the perfusion distribution is skewed (as opposed to 
simply being shifted) to higher or lower values of perfusion.  The kurtosis ( 2 ) is a measure 
of deviation of h(t) from a normal distribution and computed from: 
( ) ( )
4 / 2
4 2
2
0 0
h( )d h( )d 3t t t t t t t t
  
= −  −  − 
 
       Equation 13   
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Kurtosis is a measure of the “sharpness of the peak” of the perfusion distribution. The 
familiar Gaussian bell-shaped curve has 2 = 0; positive values of 2 indicate a sharper 
peak than a Gaussian.  The four parameters are estimated based on the above equations for 
each animal in each experimental group.  
Determining the Effectiveness of Interventions:  The effectiveness of the chronic 
interventions at improving specific biological outcomes (e.g., biomarkers, vascular function, 
behavioral scores, etc.) were calculated as: 
100
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    Equation 14 
where LZRControl and OZRControl represent the values of the measured parameter under 
untreated control conditions and OZRIntervention represents the values of the measured 
parameter as a result of chronic imposition of a given intervention under age-matched 
conditions.  This determines the % recovery in a parameter from the control condition in 
OZR, back to that in control LZR, as a result of the specific intervention. 
Statistical Analyses of Results: All data are presented as mean±SE.  Statistically 
significant differences in measured physiological parameters (e.g., arterial pressure, blood 
flow, microvessel density), calculated physiological parameters (e.g., slope coefficients, 
upper or lower bounds), measurements of plasma biomarkers, were determined using 
analysis of variance (ANOVA).  In all cases, Student-Newman-Keuls post hoc test was used 
when appropriate and p<0.05 was taken to reflect statistical significance.   
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4.4 Results 
 Table 1 presents data describing the baseline and systemic characteristics of the 
animal groups used in the present study.  By 13 weeks of age, OZR were already 
manifesting multiple elements of the metabolic syndrome as compared to LZR, including 
significant elevations in body mass, plasma insulin and glucose levels, dyslipidemia and 
markers of oxidant stress and inflammation.  These differences between LZR and OZR 
were exacerbated by 20 weeks of age, with a significant elevation in blood pressure as well.  
While single treatment with either atorvastatin or exercise was able to improve specific 
markers of the metabolic syndrome over the duration of the treatment, simultaneous 
imposition of both treatments was of greater effectiveness in terms of restoring the 
metabolic profile to that presented in control LZR.   
Table 1. Data (mean±SE) describing the baseline conditions of the animals under the conditions of the present study.  
The data in the parentheses represents the extent to which the relevant intervention restored the normal level of the 
parameter.  Please see text for details. * p<0.05 vs. LZR at that age; † p<0.05 vs. OZR at that age. 
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(Table 1 continued) 
 
 Figure 1 summarizes the data describing the dilator reactivity of ex vivo gracilis 
muscle resistance arterioles in response to increasing concentrations of acetylcholine in the 
present study.  As compared to responses in LZR, dilator reactivity in arterioles of OZR at 
13 weeks to acetylcholine was significantly reduced (Panel A).  Acute treatment of the 
vessels with TEMPOL had minimal impact on responses in LZR, but improved reactivity 
in OZR arterioles.  By 20 weeks of age, the difference in acetylcholine-induced reactivity 
was pronounced between LZR and OZR (Panel B).  While chronic treatment with ATOR 
or EXER improved responses to acetylcholine in OZR; the combination of the two 
treatments resulted in the greatest restoration of dilator responses.    Panel C presents data 
describing the impact of acute treatment with TEMPOL on the acetylcholine-induced 
gracilis arteriolar dilation in all groups of rats at 20 weeks.  While TEMPOL had negligible 
impact on responses in vessels from LZR, and the greatest impact on dilator responses in 
vessels from OZR, the impact on responses in arterioles from OZR that had been treated 
with ATOR, EXER or both were blunted as compared to that in untreated OZR.  The ability 
of the chronic interventions to restore normal dilator reactivity (determined in LZR) from 
the maximum impairment (determined in OZR) are presented in Panel D.  While both 
ATOR and EXER resulted in a significant restoration of normal function in OZR, with a 
significant additive benefit of acute TEMPOL treatment, the combination of both 
interventions resulted in the greatest degree of recovery in acetylcholine-induced responses 
with the smallest additional benefit from an acute treatment with the antioxidant.   
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Figure 1. Data (mean±SE) describing the dilator reactivity of ex vivo gracilis muscle resistance arterioles in response to 
increasing concentrations of acetylcholine.  Panel A:  data from LZR and OZR at 13 weeks of age under untreated 
conditions and following acute treatment with the antioxidant TEMPOL.  Panel B: data from LZR and OZR at 20 weeks 
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or 
both concurrently.  Panel C: the change in the upper bound of the logistic equation fit to the curves in Panel B following 
acute treatment with the antioxidant TEMPOL.  Panel D: the extent to which the different interventions restored normal 
function, and the additive benefit of acute treatment with TEMPOL.  n=6 for all groups.  For Panels A-C: * p<0.05 vs. 
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.  
Please see text for details. 
 Dilator responses of gracilis arterioles in response to hypoxia from LZR and OZR 
at 13 weeks are summarized in Figure 2, Panel A.  Hypoxic dilation in vessels from OZR 
was significantly reduced as compared to that in LZR, although acute treatment of the 
vessel with TEMPOL improved responses in vessels from OZR only.  By 20 weeks, the 
impaired hypoxic dilation in arterioles from OZR was exacerbated, and chronic treatments 
with EXER or ATOR+EXER resulted in significant improvements (ATOR alone did not 
significantly improve responses; Panel B).  Acute treatment of gracilis arterioles from the 
groups of rats at 20 weeks of age with TEMPOL had a significant impact on hypoxic 
dilation in untreated OZR and in OZR treated with chronic ATOR or EXER only (Panel 
C), while the effectiveness of the interventions on restoring normal function was similar 
between ATOR and EXER, with the combination of both being most effective, the 
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additional benefit of acute TEMPOL treatment was lowest in the ATOR+EXER group 
(Panel D).   
 
Figure 2. Data (mean±SE) describing the dilator reactivity of ex vivo gracilis muscle resistance arterioles in response to 
reduced PO2 in the chamber (hypoxia).  Panel A:  data from LZR and OZR at 13 weeks of age under untreated conditions 
and following acute treatment with the antioxidant TEMPOL.  Panel B: data from LZR and OZR at 20 weeks of age 
under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or both 
concurrently.  Panel C: the change in the dilator response in Panel B following acute treatment with the antioxidant 
TEMPOL.  Panel D: the extent to which the different interventions restored normal function, and the additive benefit of 
acute treatment with TEMPOL.  n=6 for all groups. For Panels A-C: * p<0.05 vs. LZR; † p<0.05 vs. OZR, For Panel D: 
* p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.  Please see text for details. 
 The constriction of ex vivo skeletal muscle resistance arterioles in 13-week old LZR 
and OZR following in response to increasing concentrations of norepinephrine is presented 
in Figure 3, Panel A.  At this age, there was no difference in vasoconstriction to increasing 
concentrations of the adrenergic agonist between groups.  However, by 20 weeks of age 
(Panel B), constrictor responses to norepinephrine were significantly greater in OZR vs. 
LZR, and this difference in reactivity was nearly abolished by chronic treatment with 
ATOR, EXER or both.  Acute treatment of these groups with TEMPOL improved 
responses in untreated OZR but had minimal impact on constrictor reactivity of gracilis 
arterioles from all other groups (Panel C).  The extent to which chronic ATOR, EXER or 
 109 
 
both interventions restored normal norepinephrine-induced reactivity is summarized in 
Panel D.  As compared to OZR at 20 weeks, chronic imposition of all three interventions 
resulted in an excellent recovery to normal constriction to norepinephrine, with minimal 
added benefit from acute treatment with TEMPOL.  
 
Figure 3. Data (mean±SE) describing the constrictor reactivity of ex vivo gracilis muscle resistance arterioles in response 
to increasing concentrations of norepinephrine.  Panel A:  data from LZR and OZR at 13 weeks of age under untreated 
conditions and following acute treatment with the antioxidant TEMPOL.  Panel B: data from LZR and OZR at 20 weeks 
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or 
both concurrently.  Panel C: the change in the lower bound of the logistic equation fit to the curves in Panel B following 
acute treatment with the antioxidant TEMPOL.  Panel D: the extent to which the different interventions restored normal 
function, and the additive benefit of acute treatment with TEMPOL.  n=6 for all groups.  For Panels A-C: * p<0.05 vs. 
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.  
Please see text for details. 
 The dilator response of proximal in situ cremasteric arterioles to increasing 
concentrations of acetylcholine in LZR and OZR at 13 weeks of age are presented in Figure 
4, Panel A, where responses were significantly reduced in vessels in OZR, and this 
difference was largely abolished following treatment of the cremaster muscle with 
TEMPOL.  In OZR at 20 weeks, while the differences in acetylcholine-induced dilation 
with LZR were increased, chronic imposition of ATOR, EXER or both significantly 
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improved responses (Panel B) and reduced the beneficial impact of acute TEMPOL 
treatment on dilator reactivity (Panel C).  Additionally, chronic imposition of ATOR, 
EXER or both from 13 weeks of age (with ‘both’ being most effective), significantly 
restored normal vascular reactivity to increasing concentrations of acetylcholine (Panel D).  
For distal arterioles of in situ cremaster muscle, the patterns in the data were extremely 
similar to those for proximal arterioles (data not shown). 
 
Figure 4.  Data (mean±SE) describing the dilator reactivity of in situ cremaster muscle resistance arterioles in response 
to increasing concentrations of acetylcholine.  Panel A:  data from LZR and OZR at 13 weeks of age under untreated 
conditions and following acute treatment with the antioxidant TEMPOL.  Panel B: data from LZR and OZR at 20 weeks 
of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise (EXER) or 
both concurrently.  Panel C: the change in the upper bound of the logistic equation fit to the curves in Panel B following 
acute treatment with the antioxidant TEMPOL.  Panel D: the extent to which the different interventions restored normal 
function, and the additive benefit of acute treatment with TEMPOL.  n=6 for all groups.  For Panels A-C: * p<0.05 vs. 
LZR; † p<0.05 vs. OZR, For Panel D: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ p<0.05 vs. OZR EXER.  
Please see text for details. 
 Figure 5 presents the data describing the changes in constrictor responses to 
increasing concentrations of norepinephrine for in situ cremasteric arterioles.  While there 
were minimal differences in responses at 13 weeks of age between strains (Panel A), the 
differences at 20 weeks of age were somewhat more extensive, there were no differences 
 111 
 
in reactivity that were demonstrated to be consistently statistically significant (Panel B).  
As above, for distal arterioles of in situ cremaster muscle, the norepinephrine-induced 
constriction, while potent, did not demonstrate statistically significant differences between 
LZR and OZR at either age range as such, have not been formally presented (data not 
shown). 
 
Figure 5. Data (mean±SE) describing the constrictor reactivity of in situ cremaster muscle resistance arterioles in 
response to increasing concentrations of norepinephrine.  Panel A:  data from LZR and OZR at 13 weeks of age under 
untreated conditions and following acute treatment with the antioxidant TEMPOL.  Panel B: data from LZR and OZR at 
20 weeks of age under control conditions and following 7 weeks of intervention with atorvastatin (ATOR), exercise 
(EXER) or both concurrently.   n=6 for all groups. 
 The impact of chronic interventions on the reversibility of altered wall mechanics 
in LZR and OZR gracilis arterioles are summarized in Figure 6.  At 13 weeks of age, there 
were no significant differences in the inner diameter of gracilis arterioles (Panel A), their 
incremental distensibility (Panel C) or the slope () coefficient from their stress versus 
strain relationship (Panel E).  By 20 weeks of age, arterioles from OZR exhibited a reduced 
passive inner diameter as compared to those from LZR (Panel B), with a reduced 
incremental distensibility (Panel D) and a significant left-shifting of the stress versus strain 
relationship (Panel F).  Chronic interventions with ATOR and EXER, alone or in 
combination, were largely ineffective at blunting this effect (Panel G). 
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Figure 6.  The mechanics of the wall of ex vivo gracilis muscle resistance arterioles under Ca2+-free conditions with 
increasing intralumenal pressure.  Data are presented as mean±SE.  Panel A: inner diameter of gracilis muscle resistance 
arterioles from LZR and OZR at 13 weeks.  Panel B: inner diameter of gracilis muscle resistance arterioles from LZR 
and OZR at 20 weeks under control conditions and in response to 7 weeks of intervention with atorvastatin (ATOR), 
exercise (EXER) or both concurrently.  Panel C: incremental distensibility of gracilis arterioles from LZR and OZR at 
13 weeks.  Panel D: incremental distensibility of gracilis arterioles from LZR and OZR at 20 weeks under control 
conditions and in response to 7 weeks of intervention with ATOR, EXER or both. Panel E: circumferential stress versus 
strain relationship between gracilis arterioles from LZR and OZR at 13 weeks with the determination of the slope ( ) 
coefficient. Panel F: stress versus strain relationship between gracilis arterioles from LZR and OZR at 20 weeks under 
control conditions and in response to 7 weeks of intervention with ATOR, EXER or both with the determination of the 
slope ( ) coefficient.  n=6 for all groups.  * p<0.05 vs. LZR; † p<0.05 vs. OZR.  Please see text for details. 
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 Figure 7 presents data describing the gastrocnemius muscle microvessel density 
(Panel A) and the extent of recovery in MVD as a result of the chronic interventions (Panel 
B) in LZR and OZR.   At 13 weeks of age, there was a reduction in MVD between LZR 
and OZR, which became much more pronounced by 20 weeks of age.  This difference was 
largely unaffected by chronic treatment with ATOR and only marginally affected by 
chronic EXER from 13 weeks of age in OZR.  However, combined imposition of both 
interventions resulted in a significant improvement in skeletal muscle MVD in OZR.   
 
 
Figure 7.  Microvessel density within gastrocnemius muscle of LZR and OZR under the conditions of the present study.  
Data (mean±SE) are presented for animals at 13 weeks of age and at 20 weeks of age under control (untreated) conditions 
and in response to 7 weeks of ATOR, EXER or both interventions imposed concurrently (Panel A).  Panel B presents the 
extent to which the different chronic interventions restored normal levels of microvessel density in OZR.  n=6 for all 
groups.  Panel A: * p<0.05 vs. LZR; † p<0.05 vs. OZR.  Panel B: * p<0.05 vs. no change; † p<0.05 vs. OZR ATOR; ‡ 
p<0.05 vs. OZR EXER.  Please see text for details. 
Data describing the perfusion distribution coefficient (), in both the proximal 
(Panel A) and distal (Panel B) cremasteric microcirculation are summarized in Figure 8.  
These data suggest that there were minimal differences in the average magnitude of  
between LZR and OZR at 13 weeks of age, although the temporal variability in  over the 
data collection window was reduced in OZR.  In contrast,  was increased, and its 
variability reduced, in OZR at 20 weeks of age versus LZR, and chronic imposition of 
ATOR, EXER or both from 13 weeks of age resulted in improvements to  and a greater 
degree of variability as compared to responses in untreated OZR.  These results were 
consistent in both proximal (Panel A) and distal (Panel B) arteriolar bifurcations within the 
cremasteric microcirculation. 
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Figure 8. Perfusion heterogeneity () at proximal (~70 m diameter; Panel A) and distal (~30 m diameter; Panel B) 
arteriolar bifurcations within in situ cremaster muscle of LZR and OZR under the conditions of the present study.  Data 
(mean±SE) are presented for animals at 13 weeks of age and at 20 weeks of age under control (untreated) conditions and 
in response to 7 weeks of ATOR, EXER or both interventions imposed concurrently (Panel A).  n=6 for all groups.  * 
p<0.05 between variability in group vs. LZR variability; † p<0.05 between variability in this group vs. OZR variability.  
Please see text for details. 
 Figure 9 summarizes the bioavailability of vasoactive metabolites that have been 
previously demonstrated to play a contributing role in the vascular phenotypes discussed 
above.  Vascular nitric oxide bioavailability (Panel A) was reduced in arteries of OZR as 
compared to that in LZR at 13 weeks, and this was exacerbated by 20 weeks.  Chronic 
intervention with ATOR, EXER or both resulted in a significant improvement in levels of 
NO bioavailability at 20 weeks of age in OZR.  Vascular hydrogen peroxide levels, 
elevated in arteries of OZR versus LZR at 20 weeks of age (Panel B), demonstrated a higher 
degree of variability and, although presenting a mirrored trend as compared to NO, did not 
produce a consistently significant outcome subsequent to the interventions.  A similar 
pattern to that for NO was determined for PGI2 bioavailability (Panel C), although the 
ability of the interventions to restore normal levels was less robust.  Conversely, TxA2 
bioavailability (Panel D) was significantly increased by 13 weeks of age in arteries of OZR 
as compared to that in LZR, and this elevation was only reduced at 20 weeks following 
combined imposition of ATOR and EXER from 13 weeks of age in OZR.   
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Figure 9.  Data describing the bioavailability of signaling molecules associated with healthy and impaired vascular 
function.  Data (mean±SE) are presented for the bioavailability of nitric oxide (NO, Panel A), hydrogen peroxide (H2O2, 
Panel B), prostacyclin (PGI2, Panel C) and thromboxane A2 (TxA2, Panel D).  n=6 for all groups. * p<0.05 vs. LZR; † 
p<0.05 vs. OZR.  Please see text for details. 
 The results of the in-situ gastrocnemius muscle performance experiments are 
summarized in Figure 10.   At 13 weeks of age OZR demonstrated an accelerated muscle 
fatigue rate as compared to LZR after 3 minutes of contraction at both 3Hz an 5Hz 
(isometric twitches), with the difference being exacerbated at 5Hz (Panel A).  This 
impaired muscle performance was increased at 20 weeks of age, and was not significantly 
impacted by ATOR or EXER, but only in response to the combination intervention.   The 
functional hyperemic response to muscle contraction was similar between LZR and OZR 
at 13 weeks but was attenuated by 20 weeks for both 3Hz and 5Hz contractions (Panel B).  
All three interventions were successful at significantly improving the bulk hyperemic 
response to both levels of increased metabolic demand following chronic intervention from 
13 weeks.  Oxygen extraction (Panel C) and VO2 (Panel D) across the muscle, while 
comparable in LZR and OZR at 13 weeks, were reduced by 20 weeks of age.  While ATOR 
and EXER alone resulted in mild improvements that were not statistically significant for 
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extraction of VO2, the combination of the two interventions restored both parameters to 
levels that were not significantly different from that in LZR (at 3Hz only). 
 
 
Figure 10.  Vascular responses and contractile performance of in situ skeletal muscle of LZR and OZR at 13 weeks of age 
and at 20 weeks of age under control (untreated) conditions and in response to 7 weeks of intervention with atorvastatin 
(ATOR), treadmill exercise (EXER) or both concurrently.  Data (mean±SE) are presented from the animal groups in response 
to three minutes of muscle contraction at 3 or 5Hz (isometric twitch).  Data are presented for the percentage of the peak force 
development after three minutes of the contraction bout (Panel A), the hyperemic responses to muscle contraction (Panel B), 
oxygen extraction across the gastrocnemius muscle (Panel C), and oxygen consumption across the gastrocnemius muscle 
(Panel D).  n=6 for all groups.  * p<0.05 vs. LZR; † p<0.05 vs. OZR.  Please see text for details. 
 Figure 11 presents data describing the average tracer washout from the in situ 
gastrocnemius preparation under rest conditions across the different experiment groups of 
the present study.  The appearance of 125I-albumin in the venous effluent draining the 
gastrocnemius muscle in all groups in the present study is represented in Panel A.  Figure 
12 summarizes data describing the aggregate washout curves.  Mean transit time of the 
tracer across the gastrocnemius was very similar across all groups, suggesting that the 
relationship between bulk blood flow to the gastrocnemius muscle and vascular volume in 
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the different groups was not significantly different in the present study (Panel A).  The 
relative dispersion of tracer across the muscle (RD; Panel B) was elevated in untreated 
OZR at 20 weeks of age as compared to all other groups, suggestive of an increased 
perfusion heterogeneity throughout the microcirculation of the gastrocnemius muscle.  
While treatment with ATOR was ineffective at restoring RD, chronic exercise, alone or in 
combination with ATOR, was superior at restoring RD toward levels determined in age-
matched LZR.  Both the skewness (Panel C) and the kurtosis (Panel D) of the tracer 
washout curves were reduced in OZR as compared to age-matched LZR, and these shifts 
in the washout patterns were improved toward that determined in LZR as a result of either 
ATOR, EXER or both interventions imposed concurrently.   
 
Figure 11.  Data describing the tracer washout of 125I-albumin from the in situ gastrocnemius muscle of LZR and OZR 
under the conditions of the present study.  Data (mean±SE) are presented for LZR and OZR at 13 weeks of age and at 20 
weeks of age under control (untreated) conditions and in response to 7 weeks of intervention with atorvastatin (ATOR), 
treadmill exercise (EXER) or both concurrently.  Please see text for details; n=5 for each group. 
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Figure 12.  Data (presented as mean±SE) describing the four moments of the washout of 125I-albumin from the in situ 
gastrocnemius muscle for LZR and OZR at 13 weeks of age and at 20 weeks of age under control (untreated) conditions and 
in response to 7 weeks of intervention with atorvastatin (ATOR), treadmill exercise (EXER) or both concurrently.    Data are 
shown for the mean transit time of the washout (Panel A), the relative dispersion of the washout (RD; Panel B), the distribution 
skewness (Panel C) and kurtosis (Panel D).  Please see text for details; n=5 for each.  * p<0.05 vs. LZR; † p<0.05 vs. OZR. 
 
 
 
 
 
 
 
 119 
 
4.5 Discussion 
 The powerful association between chronic metabolic disease and the increased risk 
for the development of PVD has been well known for many years.  While there have been 
many studies seeking to understand the mechanisms underlying the compromised vascular 
function under these conditions, or how interventional strategies could serve to blunt the 
development of the poor vascular outcomes (please see Ref. 33 for a recent review), an 
understanding of the outright reversibility of established vasculopathy in translationally 
relevant models has been more elusive.  This is particularly troubling, as it is this challenge 
which is most clinically relevant, where patients present themselves in a clinical setting 
only once they have already experienced the manifestations of PVD (e.g., rapid muscle 
fatigue, pain upon exertion, etc.).  The purpose of this study was to use the OZR model of 
the metabolic syndrome, at an age where impairments to skeletal muscle microvascular 
structure and function have already been established, and where impairments to hyperemic 
responses and muscle performance are still mild, to determine the extent to which 
clinically-relevant interventions could improve not only microvascular reactivity and 
structure, but also muscle fatigue and hyperemia with increased metabolic demand. 
 At 13 weeks of age, the presence of the metabolic disease in OZR was associated 
with impaired endothelial function, reduced microvessel density and initial evidence of 
impaired muscle performance and active hyperemic responses.  As severity of the 
metabolic syndrome progressed, impairments to microvascular structure and function 
increased to include an increased stiffening of the arteriolar wall, an increasing (and 
increasingly stable) heterogeneity of perfusion at arteriolar bifurcations and a worsening 
of skeletal muscle perfusion and oxygen exchange.  While this is not novel information 
and has been described previously, it does set the appropriate context for the present study:  
the vasculopathy associated with the metabolic syndrome at 13 weeks of age was present, 
was sufficient to impact skeletal muscle performance, and continued to evolve naturally 
over the subsequent 7 weeks to further compromise muscle blood flow and performance. 
 Chronic ingestion of atorvastatin from 13 weeks of age or chronic imposition of 
treadmill exercise demonstrated some effectiveness at improving vascular, and by 
extension muscle blood flow and performance, outcomes in OZR as compared to no 
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intervention, but even the combination of the two had clear limits on effectiveness.  Under 
all three interventions, with the combination of both atorvastatin and exercise being most 
effective, the improvement to the vasoactive metabolite profile – associated with the 
improvement in oxidant stress and inflammation levels – was critical for improving 
vascular reactivity to acetylcholine, hypoxia and norepinephrine.  In addition, there were 
some improvements to microvessel density, although the extent of the rarefaction even 
with the combined interventions remained considerable in the OZR despite 7 weeks of 
aggressive treatment.  Further, there was very little change in the progression of altered 
wall mechanics in the arterioles of OZR, regardless of intervention.   
 While the structure of the microvascular networks was resistant to improvement 
following intervention, there was an improvement in both the magnitude and in the 
variability of  throughout the microcirculation of OZR with chronic atorvastatin, exercise 
or both.  This was evident in both the direct observations of the microvascular networks in 
the cremaster or using the tracer washout curve analyses for the labeled albumin.  These 
results suggest that the increased heterogeneity of perfusion distribution that accompanies 
progressive metabolic disease in OZR can be partially reversed with aggressive 
intervention, even with established dysfunction.  The combination of these improvements 
to reactivity, and especially to perfusion distribution, was associated with improvements to 
muscle performance, hyperemic responses and oxygen exchange for skeletal muscle in 
OZR.  However, as recovery was most clearly evident at 3Hz contraction, as it seemed that 
5Hz contraction frequency have been too severe a challenge for any significant recovery 
to have been evident. 
 A study of this scope and focus immediately lends itself to a wide array of 
provocative questions, some of which we will attempt to address or clarify in the 
succeeding paragraphs.  Obviously, one question that immediately comes to mind is the 
timing of the intervention and its duration.  We elected to use 13 weeks of age for two 
major reasons.  First, the vasculopathy was established at this age and was beginning to 
impact muscle blood flow and performance, so this was considered to be the earliest time 
point that was relevant for “reversing” rather than for “blunting development” of vascular 
dysfunction.  Secondly, in preliminary studies, 15 weeks of age was also considered as an 
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option for the initiation of intervention due to the greater establishment of vasculopathy.  
However, it was rapidly determined that the exercise intervention was not feasible as OZR 
at that age were not able to consistently exercise without invoking a level of attrition that 
made the experiments unrealistic.   
The use of the 7 weeks of intervention was selected for two reasons as well.  First, 
using a 4-week intervention, which would bring animals to the ~17-week age range we 
have employed historically, was not considered to of sufficient duration to determine any 
meaningful outcome.  Second, using a 7-week intervention duration brings us to a 20-week 
old OZR, which we have determined is the maximum age we have been able to employ 
before changes to skeletal muscle function (e.g., Ca2+ handling, half relaxation time, 
maximal twitch tension, fiber type distribution) become too great to allow for an accurate 
interpretation of the data.   
The failure of arteriolar wall mechanics to demonstrate any significant 
improvement with intervention or, given its lack of presence at 13 weeks of age in OZR, 
could actually be considered as an appearance of the dysfunction despite the interventions, 
was a particularly striking observation of the present study.  While the mechanisms 
underlying the progressive reduction in vascular wall distensibility with metabolic disease 
(in OZR and in other models) are a continuing area of active investigation, it may be that 
the combination of atorvastatin and exercise are simply “off target” for preventing vascular 
wall remodeling.  In our previous studies, the increased stiffness of the arteriolar wall in 
OZR was associated more with the development of hypertension rather than with impaired 
glycemic control or dyslipidemia (18), and previous studies using interventions specifically 
targeted at reducing blood pressure have been more effective at moderating the changes to 
vascular wall structure and mechanics (30). 
The relatively modest responses at improving microvessel density are also 
intriguing, as previous studies have clearly demonstrated that chronic atorvastatin 
treatment and/or exercise from a relatively young age and severity of the metabolic 
syndrome was effective at blunting rarefaction severity in skeletal muscle of OZR (14).  
However, it seems plausible that the use of the 13 week age for the start of intervention, 
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while justifiable from the perspective of translational relevance, may have missed the 
window when the extent of rarefaction is most modifiable.  In a recent study examining the 
temporal nature and mechanistic bases of rarefaction in skeletal muscle of OZR, it was 
evident that the initial phase of rarefaction occurs prior to 10-12 weeks of age in OZR and 
was most closely predicted by the severity of both inflammation and vascular production 
of TxA2 (14).   For maximal effectiveness, it was proposed that interventions against 
rarefaction should be initiated prior to 10 weeks of age in OZR, although this is somewhat 
problematic as there is no functional phenotype associated with these early changes to 
microvessel density that has been identified.  Regardless, it seems likely that the optimal 
window for intervening against microvessel loss in skeletal muscle rarefaction in OZR may 
have been missed with interventions starting only after 13 weeks of age.  However, it must 
be emphasized that we have only used a 7-week intervention duration.  Whether a longer 
duration of atorvastatin treatment, exercise regimen or both (or some other intervention), 
would result in a greater degree of reversibility of the skeletal muscle microvascular 
impairments will require dedicated study. 
An additional issue that requires some comment is the observation that, while there 
were significant improvements to the reactivity of arterioles from the gracilis muscle, 
muted improvements to the microvessel density of the gastrocnemius muscle, and 
improvements to the performance, blood flow, oxygen handling and tracer washout 
kinetics indicative of a less heterogeneous perfusion distribution within the in situ 
gastrocnemius muscle of OZR, this study also presents data describing the improvement to 
the hemodynamic control of perfusion distribution in the in situ cremaster muscle – a tissue 
that is not involved in the exercise training regimen and that does not directly benefit from 
the effects of the chronic exercise (with or without concurrent atorvastatin therapy).  This 
provides strong support that the improved systemic effects of chronic exercise therapy in 
OZR, which can include an improved endocrine, oxidant stress and pro-inflammation 
status, can be highly effective in terms of improving vascular function and may work in 
combination with direct effects in the exercising muscles of interest to produce a system-
wide improvement to vascular health under conditions of the metabolic syndrome.  
However, caution must be employed when interpreting some of the results of the present 
study.  The measurement of vascular metabolites that can impact the regulation of tone 
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used larger arteries and not resistance arterioles.  While this allowed us to reduce animal 
number and provide insight into “within animal” comparisons, it must be remembered that 
vascular environments are different between larger arteries and resistance arterioles, with 
the potential for introducing inaccuracy in terms of assessing the importance of the 
metabolites to tone regulation. 
Given the results of the present study, it may be appropriate to speculate on not just 
the effect of the interventions on the potential for reversibility of established vasculopathy 
(or potential mechanisms), but also on whether the effects of these interventions can be 
additive or potentially synergistic.  It has been well established that both ATOR and EXER 
can improve anti-inflammatory and anti-oxidant capacity, thereby improving vascular 
function and health outcomes through those mechanistic pathways.  However, results from 
the present study suggest that this effect is more diverse than a single issue, such as 
improved nitric oxide bioavailability and may also include a partial restoration of vascular 
arachidonic acid metabolism.  This beneficial effect appears to be localized primarily to 
the endothelial cell as responses vascular smooth muscle-dependent stimuli were largely 
unaffected.  Further, over the time course of the present study, the impacts of the 
interventions did not significantly reverse vascular structure, either at the individual vessel 
or whole network levels of resolution.  While it is possible that a longer duration 
intervention might improve the structural characteristics of the vasculature, we may simply 
have intervened outside of the most appropriate window of time to elicit a beneficial 
outcome (14).    Regardless, although the design of the current study does not allow for a 
rigorous assessment of whether the interventions were additive or synergistic at this time, 
it is clear that the combination therapy is sufficiently robust that it helps to restore not just 
hyperemic responses and muscle fatigue rates, but also perfusion distribution, and thus O2 
delivery, patterns within the skeletal muscle. 
 In summary, the results of the present study provide compelling evidence that the 
imposition of two clinically-relevant interventions (atorvastatin and chronic exercise), 
alone or in combination to an OZR with a pre-existing established vasculopathy can result 
in improvements to specific indices of vascular reactivity, hemodynamics, blood flow, 
oxygen handling and muscle performance.  Further, these improvements appear to be 
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clearly tied to the effects of both interventions on enhancing oxidant stress and pro-
inflammation severity system-wide.  The use of statins has been shown to result in 
improved patency and limb salvage rates in patients undergoing revascularization for limb 
ischemia (1). The specific mechanisms underlying this effect remain unclear. Perhaps these 
improvements in microvascular dysfunction observed in this animal model help to explain 
this clinical association in humans.   Indices of altered vascular structure, both at the 
individual vessel and whole network levels of resolution were more resistant to 
reversibility with the selected interventions and their duration, although determining if this 
represents specific procedural issues with the present study or simply processes that are 
more difficult to reverse will require further investigation.  Regardless, the results of the 
present study provide compelling insight and provocative direction for future study into 
the reversibility of established vasculopathies under condition of chronic metabolic disease 
and may have implications for primary and secondary prevention of PVD. 
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Chapter 5 
5 Thesis Conclusion 
 Approximately 20% of the adult population is afflicted with Metabolic Syndrome 
(METS; Riediger & Clara, 2011) which is the presentation of obesity, dyslipidemia, 
hypertension, and insulin resistance. METS increases the risk of cardiovascular disease 
(CVD) by 2.6-fold and type 2 diabetes mellitus (T2DB) by 5-fold (Lakka, 2002). 
Additionally, almost 40% of adults with METS over the age of 40 are afflicted with 
peripheral vascular disease (PVD), the presentation of poor skeletal muscle blood 
perfusion with increases in metabolic demand (Sumner et al., 2012). Thus, this perfusion-
demand mismatch typically gives rise to increases in muscle fatigue and pain during 
times of increased physical activity (Abdulhannan et al., 2012). The purpose of this 
dissertation is to generate novel insights for both venular and arteriolar micro-
vasculopathies using the translational animal model for METS, the obese Zucker rat 
(OZR), and to investigate the potential reversibility of established PVD using exercise 
and atorvastatin. 
Chapter 1: Altered Postcapillary and Collecting Venular Reactivity in Skeletal Muscle 
with Metabolic Syndrome 
 Retinal microcirculation studies have provided insight to alterations in venular 
function with METS and how the control of venular diameter and venular network 
structure can be significantly impacted (Lammert et al., 2012). While there are some 
studies dedicated to venular function in the context of leukocyte interactions within the 
venular walls in inflammation (Iba et al., 2012), there is limited information pertaining to 
these dysfunctions in relevant animal models for METS and PVD. These experiments 
sought to identify any alterations in postcapillary and collecting venule function in the 
OZR compared to healthy controls.  
 The OZR presented with impaired dilator reactivity in both postcapillary and 
collecting venules which was attributed to elevations in reactive oxygen species and its 
negative effects on venular nitric oxide and prostacyclin bioavailability. Further, 
 130 
 
elevation in adrenergic and thromboxane A2 constrictor responses may contribute to the 
impaired dilator responses. Taken together, these disparities indicated an altered 
microvascular reactivity at the venular level of skeletal muscle, thereby providing insight 
to an area of METS vasculopathy which has received little investment. Where this fits in 
the context of METS microcirculatory research, as a whole, is a starting point for 
potential, compelling avenues of future research. Previous studies have shown some of 
the earlier, measurable changes to the microcirculation occur on the venular side (with 
respect to leukocyte rolling and adhesion) in METS. The current study shows apparent 
differences in vascular reactivities, with METS risk factors, which favor that of a more 
vasoconstrictive state. While it is known that venules and veins do not necessarily change 
resistance to restrict blood flow, but rather compliance to facilitate it (Rothe, 1983). 
Therefore, the speculation can be made that the observable differences may be either an 
adaptation to the existing microvasculapathies or a potential contributor to their severity. 
Nevertheless, the changes are apparent and additional, dedicated studies are required to 
further investigate these changes with respect to identifying the nature of their existence. 
 
Chapter 2: Altered Distribution of Adrenergic Constrictor Responses Contributes to 
Skeletal Muscle Perfusion Abnormalities in Metabolic Syndrome 
 Adrenergic traffic, signaling, and vascular responses may be elevated with METS 
risk factors (Carlson et al., 2000; Naik et al, 2006; Frisbee 2004). Treatment with α-
adrenoreceptor antagonists equalizes the elevated blood pressure of the OZR to levels 
comparable to healthy controls. However, it is unclear how general elevations in vascular 
adrenergic output, which produces significant elevations in resistance, functions in vivo 
to produce mild/moderate elevations in blood pressure observed in OZRs (Tofovic et al., 
1998; Frisbee, 2004). Therefore, these experiments sought to reveal potential contributors 
of this disconnect using a multi-scale/resolution approach, thus garnering a greater 
understanding of the impaired adrenergic control for PVD within METS. 
 The OZR experienced an increased α1 adrenoreceptor mediated, whole-animal 
pressor response compared to healthy controls, independent of reactive oxygen species or 
nitric oxide bioavailability. However, the blunted in situ hyperemic response in the OZR 
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was mediated, in part, by reactive oxygen species (ROS) as the combination of TEMPOL 
(ROS scavenger) and α1-adrenoreceptor inhibition elicited the greatest improvements in 
muscle performance and volume of oxygen consumption. With a minor adjustment of the 
classically used inclusion criteria for experiments of this nature, high resolution 
interrogations of the in-situ cremaster muscle arterioles and ex vivo gracilis muscle artery 
revealed an α1-adrenoreceptor mediated hyperresponsiveness with OZR vessels, 
contributed to by ROS and nitric oxide bioavailability. Lastly, OZR arteriolar responses 
to an α1 adrenoreceptor challenge revealed a more heterogeneous, constrictor response 
compared to healthy controls. While these results support α1 adrenoreceptor as a key 
contributor to the elevated pressor responses and vascular resistance in the OZR, the 
purpose of a more heterogeneous response is unclear. 
 
 In the context of METS microvasculopathy research, it is well established α-
adrenoreceptor stimulated vasoconstrictor responses are elevated for subjects with METS 
associated vascular dysfunction. Therefore, the current adrenergic literature emphasizes 
investigation on biochemical signaling pathways and secondary messengers that may 
contribute to the differences in response for the OZR versus healthy controls. While the 
pathways are essential to understanding the underlying pathologies, it is critical we 
continue to interrogate the functional outcomes of these pathologies as there are 
important questions which remain unanswered. The current study, in part, provides 
insight for the discrepancies of in vivo blood pressure responses and ex vivo vascular 
responses observed with the OZR model. In doing so, changes in variance and frequency 
distributions were coupled to these apparent differences in vascular response giving rise 
to further questions. A speculative purpose for this phenomenon may include that of a 
shift in initial tangential stresses due to changes in pressure and wall thickness in the 
OZR vessels, thereby influencing vascular responses (described by Gore et al., 1972). 
However, additional studies are necessary to explore this potential phenomenon.   
Chapter 3: Chronic Atorvastatin and Exercise can Partially Reverse Established Skeletal 
Muscle Microvasculopathy in Metabolic Syndrome 
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 The final set of experiments are dedicated to reversing established METS 
associated vasculopathies of the skeletal muscle. Previous studies demonstrate a loss in 
microvascular density (rarefaction) and function in parallel to the development of 
metabolic syndrome (Machado et al., 2016). While there are interventional strategies to 
decrease the severity of these vasculopathies, there is limited research on the restoration 
or reversibility of vascular health following the onset of these vasculopathies. 
Consequently, these experiments sought to determine the potential for reversibility or 
restoration of established PVD using the chronic ingestion of an HMG-CoA inhibitor, 
atorvastatin (ATOR), and/or the implementation of regular exercise (EXER). 
 
 In the current study, following the establishment of PVD at 13 weeks of age, a 7-
week intervention was implemented in which the ATOR group and EXER group 
experienced significant improvements compared to time control OZRs while the 
combination group of ATOR and EXER elicited the greatest degree of reversibility, in 
certain criteria. There were favorable changes to vasoactive metabolite bioavailability, 
reactivity, and perfusion distributions, thereby resulting in better muscle performance and 
oxygen transport during stimulated muscle contractions compared to the time control 
OZR group. With respect to the stated definition of reversibility, these improvements 
were more comparable to the measured values of the healthy controls, indicating a 
potential for reversibility of established PVD, within specific parameters. 
  
 While improvements to microvascular density were modest and there were no 
significant improvements in wall mechanics, microvascular densities of the intervention 
OZR groups did improve compared to the 20-week OZR time control.  Those 
improvements were comparable to the 13-week OZR time controls. This may be 
interpreted as a blunting effect rather than restorable indicating a low potential for 
reversibility. A lack of significant structural improvements may have resulted from 
missing the appropriate interventional window (Frisbee et al., 2014) or potentially the 
short duration of the intervention as Orr et al. reported improvements in the vessel 
mechanics in humans following a 12-week ATOR intervention. However, the current 
study using the OZR model is restricted to a narrow interventional window for an 
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accurate assessment of established PVD (details in chapter 4 discussion; Orr et al., 2009). 
Nevertheless, ATOR and EXER can significantly reverse specific indices of 
microvascular function following established vasculopathy in the OZR thus representing 
an effective avenue for interventions aimed at reversing microvasculopathies.  
 
 It is well established both forms of intervention possess anti-inflammatory and 
anti-oxidant properties which can improve vascular health. Previous literature utilizing 
both ATOR and EXER as primary and secondary (respectively) forms of treatment have 
been shown to improve blood flow in health and with cardiovascular disease in humans. 
Exercise has been shown to improve blood flow via mechanisms including increases in 
eNOS expression, improved anti-oxidant systems, and decreases in NADPH oxidase 
generated reactive oxygen species (Machado et al., 2016; Rush et al., 2003). Although the 
mechanisms are unclear, ATOR has been shown to improve vascular outcomes for 
inflammation related diseases by means of decreasing the expression of IL-6 and TNF-α, 
decreasing CRP production, and upregulation of anti-oxidant systems (Rabkin et al., 
2013; Sodha et al., 2015). While speculation that a combination of these two treatment 
methods elicit the greatest potential for PVD reversibility can be made, it is not known if 
the improvements are synergistic or additive in a model for METS. Although the 
existence of synergy between the two treatment methods has been shown in 
atherosclerotic mice (Moustardas et al, 2014), the current study’s design does not allow 
for such an assessment. Due to this, additional studies are required to garner a greater 
understanding of the synergistic capacities for EXER and ATOR. 
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